

**CURRICULUM VITAE**

*Vip Viprakasit, M.D., D. Phil. (Oxon)*

*Professor of Pediatrics*

---

## PERSONAL INFORMATION

Name : Vip Viprakasit

Qualification: M.D. (first class honours), Mahidol University, Bangkok, Thailand.  
Certificate in Clinical Science (Paediatrics), Chiang Mai University.  
Diploma Thai Board of Paediatrics (Medical Council of Thailand).  
D. Phil. in Molecular Medicine from Department of Human Anatomy and Genetics, University of Oxford, UK.  
Postdoctoral Fellowship in Molecular Haematology, Weatherall Institute of Molecular Medicine, University of Oxford, UK.

Sex : Male

Nationality : Thai

Date of Birth : September 12<sup>th</sup>, 1970

Contact address: Division of Haematology-Oncology  
Department of Paediatrics  
Faculty of Medicine Siriraj Hospital, Mahidol University  
Bangkok 10700, Thailand

Home address : 101/356 Soi 12 A, Preecha Village, Phuthamontol IV Rd., Sampran,  
Nakornpathom, Thailand

Telephone : (+66)-2-4197000 ext. 9363 (office) and (+66)-85-8076859 (mobile)

Fax : (+66)-2-4122113

E-mail : vip.vip@mahidol.ac.th.

## CURRENT STATUS

*Professor of Pediatrics*, Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand, since May 2015.

*Programme Director for Thalassemia & Haemoglobinopathies Research*, WHO Collaborating Centre for Prevention and Control of Thalassemia and Haemoglobinopathies, Bangkok 10700, Thailand, since 2007.

## EDUCATION AND TRAINING

### *Postgraduate:*

|                           |   |
|---------------------------|---|
| June 2006                 | Clinical Research & Good Clinical Practice (GCP) training, Asia-Pacific Hematology-Oncology Academy (APHOA), Taipei   |
| July 2005 – August 2005   | Training in advance Molecular Haematology, Weatherall Institute of Molecular Medicine, Oxford   |
| August 2005               | Training in multiple ligation probe associated assay (MLPA), University of Leiden, The Netherlands.   |
| November 2002-August 2004 | Postdoctoral fellowship in Molecular Haematology under the supervision of Professor Douglas R. Higgs, Director of MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford  |
| March 2003                | An introductory course for microarray analysis, Sanger Center for Human Genetics, Cambridge, UK   |
| January 2000-October 2002 | D. Phil. candidate at Department of Anatomy and Genetics, University of Oxford under the supervision of Professor Douglas R. Higgs, MB, DSc, FRCP, FRCPath, FRS and Professor Kay E. Davies, Ph.D., OBE, FRS<br>Professor of Anatomy, Chairman of Department of Human Anatomy and Genetics, Oxford                                      |
| August-December 1999      | Visiting research fellow at MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford  |
| August 1998               | Epidermiology and Statistics Course for Clinical Research Faculty of Medicine at Siriraj Hospital, Mahidol University, Thailand   |
| April 1998                | Molecular biology techniques for thalassaemia research, Thalassaemia Research Centre, Institute of Science and Technology for Research Centre, Mahidol University, Thailand   |
| January- December 1997    | Chief Resident in Paediatrics (Registrar equivalent)<br>Full responsibility for management of 70 bed-pediatric unit.<br>Coordinate and manage 30-paediatric resident duty and rotation. Administer academic activities such as medical grand round, article review, journal club, interesting cases and clinicopathological conference. |

|                           |   |
|---------------------------|---|
| April 1995- December 1997 | Paediatric Residency Training Programme, Department of Paediatrics, Faculty of Medicine, Chiang Mai University, Thailand. |
| April 1994- May 1995      | Postgraduate Training in Clinical Science (Paediatrics), Faculty of Medicine, Chiang Mai University, Thailand.            |

### *Undergraduate:*

|                     |   |
|---------------------|---|
| April 1988-May 1994 | Undergraduate medical training , Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand. |
|---------------------|---|

### **HONOURS AND AWARDS**

- Medical degree with first class honours, 1994.
- Honourable medal for the highest total marks in Internal Medicine, 1992-1994.
- Professorial award for the best medical student in Internal Medicine, 1992-1994.
- Prince Mahidol Fellowship from the Thai government between 1999-2002.
- British Journal of Haematology Research Trust Travel Grant (£ 1000) to attend and present a poster at the 12<sup>th</sup> Conference on Haemoglobin Switching, June 9-13, 2000 at Seattle, USA.
- Travel Award from European Society of Haematology for one of the best abstracts presented in the 6<sup>th</sup> European Haematology Association Meeting (EHA), June 21-24, 2001 at Frankfurt, Germany.
- Medical Research Fund Award for the cost of attending and presenting an oral paper in the 8<sup>th</sup> International Conference on Thalassaemia, October 18-21, 2001 at Athens, Greece.
- Medical Research Fund Award for the cost of attending and presenting two oral papers in the 9<sup>th</sup> International Conference on Thalassaemia, October 16-19, 2003 at Palermo, Italy.
- Medical Research Council Award for the cost of attending and presenting an oral paper in the 43<sup>rd</sup> Annual Meeting of American Society of Haematology, December 7-11, 2001 at Orlando, Florida.
- Medical Research Council Award for attending the 44<sup>th</sup> Annual Meeting of American Society of Haematology, December 6-10, 2002 at Philadelphia, Pennsylvania.
- Medical Research Council Award for attending the 45<sup>th</sup> Annual Meeting of American Society of Haematology, December 4-9, 2003 at San Diego, California.

- Travel award for attending the 46<sup>th</sup> Annual Meeting of American Society of Haematology, December 7-10, 2003 at San Diego, California.
- Methevijai Research Fellowship by Thailand Research Fund from 2005-2007.
- The 6<sup>th</sup> Prof. Alendry P. Caviles Jr. Memorial Lecturer on the topic; “Thalassemia Screening in Developing Countries” during the Philippine Society of Hematology and Blood Transfusion (PSHBT)’s 42<sup>nd</sup> Annual Convention, September 4<sup>th</sup> 2012, Crown Plaza Manila Galleria, Oritigas Avenue, Asian Development Ave., Quezon City, Philippines.
- Harvard Blood Scholar Lecturer, October 18<sup>th</sup>, 2012 on the topic; “Thalassemia Research in the Far East: When the East Meets the West”
- Sutan Bin Kalifa International Thalassaemia Award (SITA) for the Best Centre of Excellence on Thalassaemia Care, October 2013 in The 13<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies. Thalassaemia International Federation (TIF), Abu Dhabi, UAE.
- The Best Research Award of the Year 2015 from a discovery of a new hereditary haemolytic anemia condition caused by novel mechanism due to mutations of KLF-1 genes from National Research Council of Thailand (NRCT).

**TEACHING EXPERIENCE**

|                             |   |
|-----------------------------|---|
| August 2006 – present date  | Associate Professor in Paediatric Haematology |
| 2004 – July 2006            | Assistant Professor in Paediatric Haematology |
| January 1998 – October 2004 | Lecturer in Paediatrics Haematology           |

My responsibilities include clinical teaching for the forth to sixth year medical students, paediatric residents and clinical fellow in paediatric haematology-oncology, administering and working as an attending physician for the general paediatric ward and special ward for paediatric haematology patients and thalassaemia clinic at Department of Paediatrics, faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

**POSTGRADUATE SUPERVISING EXPERIENCE**

\*with the MSc-PhD program in Immunology & Molecular Medicine, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University

\*\* with the MSc-PhD program in Clinical Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University

\*\*\* Thesis for Thailand Board Certification in Pediatrics, under the Department of Pediatric, Faculty of Medicine Siriraj Hospital, Mahidol University and Medical Council of Thailand

| No. | Name-Surname             | Degree | Thesis title  | year      |
|-----|--------------------------|--------|---|-----------|
| 1   | Yuwarat Monteerarat*     | MD-PhD | Genetic susceptibility to H5N1 infection in human   | 2006-2010 |
| 2   | Supachai Ekwattanakit*   | MD-PhD | Molecular genetics and epigenetic control of $\gamma$ globin gene regulation                                | 2006-2010 |
| 3   | Warangkana Tongnoppakul* | MSc    | Molecular basis of UGT1A1 and risk of neonatal hyperbilirubinemia in Thailand                               | 2007-2010 |
| 4   | Nunthawut Chat-uthai     | MSc    | Genetic association study in pediatric sepsis and septic shock syndrome                                     | 2008-2012 |
| 5   | Suchada Riolueang *      | MSc    | Development of primary erythroid culture as a model for studies of pathophysiology in hematologic disorders | 2009-2012 |
| 6   | Nipon Chalaow            | MSc    | Molecular characterization of hereditary persistent fetal hemoglobin (HPFH) in                              | 2010-2014 |

|    |                                     |                                      | Thailand   |           |
|----|-------------------------------------|--------------------------------------|--|-----------|
| 6  | Narawadee Rujanapun                 | Msc                                  | Effects of Ag-nano particles on normal and thalassemic erythroid cells   | 2011-2014 |
| 7  | Rapeeparn Chompoopong               | Msc                                  | Proteomic analysis in Thai patients with KLF-1 disease   | 2012-now  |
| 8  | Suthatip Kainoo                     | Msc                                  | Molecular basis of rare blood group (InLu) in Thai population  | 2012-now  |
| 9  | Portep Tanyut                       | Msc                                  | Development of a simple and economical approach for prenatal and preimplantation genetic diagnosis for thalassemia and hemoglobinopathies            | 2013-now  |
| 10 | Punyanuch<br>Jindatanmanusan**      | MSc                                  | Diagnostic applications of newborn screening for $\alpha$ -thalassemias, Hb E and Hb H disorders using isoelectric focusing (IEF) on dry blood spots | 2008-2012 |
| 11 | Nuntana<br>Siripripattanamongkol*** | Pediatrics                           | Molecular basis of neonatal hyperbilirubinemia in Thailand   | 2007-2010 |
| 12 | Chulamanee<br>Chairattananon***     | Pediatrics                           | Current status of iron deficiency anemia in a hospital based study: Siriraj's experience   | 2007-2010 |
| 13 | Krongjit Lekpetch                   | Pediatric<br>Hematology<br>/Oncology | Clinical efficacy of splenectomy in pediatric patients with Hb H disease   | 2007-2008 |
| 14 | Prapa Arunyadet***                  | Pediatric<br>Hematology<br>/Oncology | Clinical manifestations and natural history in pediatric patients with red cell membrane disorders   | 2008-2009 |
| 15 | Pornpan Sripornsawan***             | Pediatric<br>Hematology              | Clinical significant adverse events after deferasirox therapy in 92 pediatric  | 2009-2010 |

|    |                            |            |   |           |
|----|----------------------------|------------|---|-----------|
|    |                            | /Oncology  | patients with $\beta$ -thalassemia  |           |
| 16 | Pimnipa Lukkanalikitkul*** | Pediatrics | Effects of short course of regular blood transfusion on growth and development in pediatric patients with Hb E/ $\beta$ thalassemia   | 2010-2013 |
| 17 | Pornnipa Tiandech***       | Pediatrics | Clinical efficacy and safety of a combination of DFO therapy in Thai patients who were non-responders to deferiprone monotherapy and a long-term efficacy in patients who were responders | 2010-2013 |
| 18 | Surapan Jenchajawarn***    | Pediatric  | Survival analysis of thalassemia patients during the past 50 years at Siriraj hospital  | 2011-2013 |

### RESEARCH INTEREST

1. Thalassaemia and haemoglobin disorders.
2. Red blood cell membrane defects and enzymopathies (esp. G6PD deficiency).
3. Regulation and transcriptional control of globin genes.
4. Bone Marrow failure syndrome in children.
5. Population and evolutionary genetics

### ONGOING RESEARCH PROJECTS AS THE PRINCIPLE INVESTIGATOR

1. Natural history, genotype-phenotype interaction in Childhood Haemoglobin H disease.
2. Natural history, genotype-phenotype interaction in Childhood Haemoglobin E/ $\beta$  thalassaemia and  $\beta$  thalassaemia major disease.
3. Identification of rare  $\alpha$  and  $\beta$  thalassaemia mutations and novel  $\delta\beta$ -thalassaemia and hereditary persistent of fetal haemoglobin (HPFH) in Thailand in collaboration with Professor Vichai Laosombat, Faculty of Medicine, Prince of Songkla University, Thailand and Associate Professor Tanyachai Sura, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand.
4. Molecular genetic and polymorphism of Alpha Haemoglobin Stabilising Protein gene (AHSP) as a potential disease-modifying factor in Haemoglobin E/  $\beta$  thalassaemia patient in



collaboration with Professor Mitchell J. Weiss, Department of Paediatrics, Faculty of Medicine, University of Pennsylvania, Philadelphia, USA.

5. Analysis of human heme-regulated translational inhibitor (HRI) gene as a potential disease-modifying factor in Haemoglobin E/  $\beta$  thalassaemia patient in collaboration with Dr. Jane-Jane Chen, The Harvard- MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.

6. Pathology of Haemoglobin Barts' hydrops fetalis in different gestational age. In collaboration with Assistant Professor Pharuhas Chanpraph, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Thailand.

7. Molecular pathology of human lysosomal-acid lipase gene causing Wolman disease in Thailand in collaboration with Professor Vichai Laosombat, Faculty of Medicine, Prince of Songkla University, Thailand.

8. International registration of survival patients with Haemoglobin Barts' hydrops fetalis syndrome, in collaboration with Professor David H. Chui, Department of Internal Medicine and Molecular Medicine, Faculty of Medicine, Boston University, USA.

9. Methylation profiling and pattern of gene expression during definitive erythropoiesis.

10. Correlation study between long-range haplotype analysis of chromosome 16 (13.3) and chromosome structure in collaboration with Dr. Ioannis Regeussis and Professor Lon Cardon, Wellcome Trust Centre for Human Genetics, University of Oxford, UK.

### EXTERNAL GRANTS AND FUNDING SUPPORTS

| No. | Project title   | Funding agency   | Study period        | Total budget granted (baht) |
|-----|---|--|---------------------|-----------------------------|
| 1.  | Understanding genotype-phenotype correlation in paediatric patients with Hb H disease   | Siriraj grant for Research Development and Medical Education, Faculty of Medicine Siriraj Hospital, Mahidol University | Nov 2004 – Oct 2006 | 1,000,000                   |
| 2.  | Molecular basis of phenotypic variability in paediatric patients with Haemoglobin E/ $\beta$ thalassaemia   | Thailand Research Fund (TRF) (Thailand Research Scholar)   | June 2005- May 2008 | 1,200,000                   |
| 3.  | Molecular epidemiology of thalassaemia in Thailand; a multicentre study   | Thalassaemia Foundation of Thailand  | Mar 2005- Feb 2006  | 350,000                     |
| 4.  | Disease modifier genes in thalassaemia  | BIOTEC (Thailand)  | Oct 2005 - Aug 2010 | 3,250,000                   |
| 5.  | A one-year, open-label, multicentre trial evaluating the efficacy and safety of oral ICL 670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload (multicentre, international trial) | Novartis, co. Ltd.   | Dec 2005 – Jan 2008 | 4,500,000                   |
| 6.  | Epigenetic control of the $\gamma$ globin genes expression in $\beta$ thalassaemia/ Hb E disease  | The Royal Golden Jubilee-PhD programme, Thailand Research Fund (TRF)   | Dec 2005 – Jan 2007 | 2,250,000                   |

## KEY CARRER PUBLICATIONS

\* as the corresponding author, <sup>§</sup>as the co-author

1. **Vip Viprakasit**, Richard J. Gibbons, Bernard C. Broughton, John L. Tolmie, Donald Brown, Peter Lunt, Robin M. Winter, Stefano Marinoni, Miria Stefanini, Louise Brueton, Alan R. Lehmann & Douglas R. Higgs. Mutations in the general transcription factor TFIID result in  $\beta$  thalassaemia in individuals with trichothiodystrophy *Human Molecular Genetics*, 2001; 15: 10 (24) 2797-2802.
2. **Vip Viprakasit\***, Voravarn S. Tanphaichitr, Parichat Pung-Amritt, Siripan Petrarat, Lerlugsu Suwanto, Chris Fisher and Douglas R. Higgs. Clinical phenotypes and molecular characterisation of Hb H-Pakse' disease. *Haematologica*, 2002; 87:117-25.
3. **Vip Viprakasit**, Alexa M.J. Kidd, Helena Ayyub and Douglas R. Higgs. *De novo* deletion within the telomeric region flanking the human  $\alpha$  globin locus as a cause of  $\alpha$  thalassaemia. *British Journal of Haematology*, 2003; 120: 867-875.
4. **Vip Viprakasit\*** & Voravarn S. Tanphaichitr. An unusual phenotype of Hb EE with Hb H disease: a pitfall in clinical diagnosis and genetic counseling. *Journal of Pediatrics* 2004; 144 (3): 391-393.
5. **Vip Viprakasit\***, Voravarn S. Tanphaichitr, Worrawut Chinchang, Mitchell J. Weiss and Douglas R. Higgs. Evaluation of Alpha Hemoglobin Stabilizing Protein (AHSP) as a genetic modifier in patients with  $\beta$  thalassemia. *Blood* 2004; 103 (9): 3296-3299.
6. A.Premawardhana, C.A. Fisher, N.F. Olivieri, S. de Silva, M. Arambepola, W. Perera, A.O'Donnell, T.E.A. Peto, **V. Viprakasit**, L. Merson, G. Muraca, D.J. Weatherall. Hb E  $\beta$  thalassaemia in Sri Lanka. *Lancet* 2005; 366(9495):1467-70.
7. **Marco De Gobbi<sup>§</sup>**, **Vip Viprakasit<sup>§</sup>**, Jim Hughes, Chris Fisher, Veronica J Buckle, Helena Ayyub, Richard J Gibbons, Doug Vernimmen, Yuko Yoshinaga, Pieter de Jong, Jan Fang Chen, Edward M Rubin, William G Wood, Don Bowden, Douglas R Higgs. A remote, gain of function regulatory SNP illustrating a novel mechanism for human genetic disease. *Science* 2006; 312(5777):1215-7.
8. **Vip Viprakasit** Alpha-thalassaemia: From Clinical and Molecular Diagnosis to Bedside Management. *Hematology Education: the education programme for the annual congress of the European Hematology Association*; 2013; 7(1); 329-338
9. **Vip Viprakasit\***, Issarang Nuchprayoon, Ampaiwan Chuansumrit, Kittit Torcharus MD, Bunchoo Pongtanakul, Jiraporn Laothamatas, Somdet Srichairatanakool, Julaporn

Pooliam, Siritwat Supajitkasem, Prapat Suriyaphol, Voravarn S. Tanphaichitr, Soodsarkorn Tuchinda. Deferiprone (GPO-L-ONE) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multi-centre prospective, single arm, open label, dose escalating Phase III study (GPO-L-ONE; A001) from Thailand. *Am J Hematol*; 2013; 88(4):251-60.

10. **Vip Viprakasit\***, Supachai Ekwattanakit, Suchada Riolueang, Nipon Chalaow, Chris Fisher, Karen Lower, Hitoshi Kanno, Kalaya Tachavanich, Sasithorn Bejrachandra, Jariya Saipin, Monthana Juntharaniyom, Kleeksabi Sanpakit, Voravarn S. Tanphaichitr, Richard Gibbons, Sjaak Philipsen, and Douglas R. Higgs. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression.. *Blood* 2014; 123(10):1586-95.

## PUBLICATIONS IN PEER REVIEWED INTERNATIONAL JOURNALS

\* as the corresponding author # as the senior author \$ as co-first author

1. Ravi Shah, Thidararat Suksangpleng, Suchada Riolveang, **Vip Viprakasit\***. Evaluation a New Screening Method for Detecting Hemoglobin E (Hb E) Using a DEAE Sephadex A50 micro-column. *Inter J Lab Hematol*; 2017: submitted.
2. Supachai Ekwattanakit, Suchada Riolveang, Nipon Chalaow, **Vip Viprakasit\*** The effect of nonsense mediated decay in transcriptional activity of the novel  $\beta$ -thalassaemia mutation Hemoglobin Yala [HBB:c.129delT]. *Hematology*; 2017: submitted
3. Supachai Ekwattanakit, David Garrick, Suchada Riolveang, Kevin Clark, Marco De Gobbi, Jackie Sloane-Stanley, Stefano Colella, Jiannis Ragoussis, Douglas R. Higgs, and **Vip Viprakasit\***. Epigenetic analysis of beta-globin gene cluster during hematopoiesis: a possible role of DNA methylation on regulation of gene expression at beta-globin locus control region and its linked promoters. *Exp Hematol*; 2017 submitted
4. **Vip Viprakasit\*** & Surakarn Jansutjawan. Survival and causes of death in patients with  $\alpha$ - and  $\beta$ -thalassaemia in a developing country: The First Report from Thailand. *Lancet Hematology*; submitted 2017
5. **Vip Viprakasit\***, Kevin H Kuo, Patricia J Giardina, Alan R Cohen, Ellis J Neufeld, Yesim Aydinok, Janet L Kwiatkowski, Antoine N Saliba, John C Chapin, William Kramer, Brenda I Jeglinski, Keith Pietropaolo, Gregory Berk, Ali T Taher. A Phase Ib Study Evaluating the Safety and Pharmacokinetics of SP-420, a Novel Iron Chelator for Transfusional Iron Overload. *Haematologica* 2017; submitted
6. Kleesabai Sanpakit, Bunchoo Pongtanakul, Nattee Narkbunnam, **Vip Viprakasit**, Gavivann Veerakul, Voravarn S.Tanphaichitr, Surapol Issaragrisil, Vinai Suvatte. How can we get the best outcomes from Cord Blood Stem Cell Transplantation (CBSCT) in children with severe thalassemia patients: When the cell number is really matter. *Southeast Asian J Trop Med Public Health* 2017; in press.
7. Supachai Ekwattanakit, Pairunyar Nakavachara, **Vip Viprakasit\*** An EXCEL-based worksheet program for a rapid calculation of weight-for-age and height-for-age Z-scores in a pediatric Southeast Asian population (THAI-Z). *Southeast Asian J Trop Med Public Health* 2017; in press.
8. Supachai Ekwattanakit, Noppadol Siritanaratkul, **Vip Viprakasit\***. Characteristics and complications in non-transfusion-dependent thalassemia: comparison between splenectomized and non-splenectomized patients. *Biomed Int* 2017; in press.
9. Duantida Songdej, Ali Amid, **Vip Viprakasit**, Titi Singer, Elliott P. Vichinsky, Vivian Chan, AW Leung, CK Li, SY Ha, Melanie Kirby-Allen, Daniel E. Bauer, Yeoh Seoh Leng, Lydia H. Pecker, John Wu, Sule Unal, Fatma Gumruk, Irene Roberts, Vineet Bhandari, Peter F. Coccia, Christian Babbs, Douglas R. Higgs. The Natural History and Long-term Outcomes of Survivors with Hb Bart's Hydrops Fetalis Syndrome. *Blood* 2017; in press.

10. John B Porter, M Domenica Cappellini, Antonis Kattamis, **Vip Viprakasit**, Khaled M Musallam, Zewen Zhu, Ali T Taher. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. *Br J Haematol* 2017; 176(2): 288-299.
11. Saliba AN, Musallam KM, Cappellini MD, Graziadei G, Daar S, **Viprakasit V**, Taher AT. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. *Am J Hematol*; 2017: 92(3): E35-37.
12. Taher AT, Porter JB, Kattamis A, **Viprakasit V**, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. *Drug Des Devel Ther.* 2016; 10:4073-4078.
13. A Engert, C Balduini, A Brand, B Coiffier, C Cordonnier, H Döhner, TD de Wit, S Eichinger, W Fibbe, T Green, F de Haas, A Iolascon, T Jaffredo, F Rodeghiero, G Salles, JJ Schuringa; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica* 2016; 101(2):115-208.
14. Jiang Z, Luo HY, Huang S, Farrell JJ, Davis L, Théberge R, Benson KA, Riolueang S, **Viprakasit V**, Al-Allawi NA, Ünal S, Gümruk F, Akar N, Başak AN, Osorio L, Badens C, Pissard S, Joly P, Campbell AD, Gallagher PG, Steinberg MH, Forget BG, Chui DH. The genetic basis of asymptomatic codon 8 frame-shift (HBB:c25\_26delAA)  $\beta(0)$  - thalassaemia homozygotes. *Br J Haematol* 2016;172(6):958-65
15. Wai Cheng Foong, Jacqueline J Ho1, C Khai Loh, **Vip Viprakasit**.#Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias. *The Cochrane Review* 2016;10: CD011579.
16. Ali T Taher, Maria Domenica Cappellini, Yesim Aydinok, John B Porter, Zeynep Karakas, **Vip Viprakasit**, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro, and Yong-Rong Lai. Optimizing iron chelation therapy with deferasirox for non-transfusion-dependent thalassemia patients: 1-year results from the THETIS study. *Blood Cell Molecules and Diseases* 2016; 57:23-9.
17. Narawadee Rujanapun, Sasitorn Aueviriyavit, Suwimon Boonrangsiman, Apiwan Rosena, Duangkamol Phummiratch, Suchada Riolueang, Nipon Chalaow, **Vip Viprakasit\*** & Rawiwan Maniratanachote. Human primary erythroid cells as a more sensitive alternative in vitro hematological model for nanotoxicity studies: toxicological effects of silver nanoparticles. *Toxicology In Vitro* 2015; 29(8):1982-92.
18. **Vip Viprakasit**.  $\alpha$ -thalassaemia: a genotype-phenotype correlation and management. *ISBT Science Series*; 2015: 10(Suppl. 1): 295-304.
19. Aydinok Y, Kattamis A, Cappellini MD, El-Beshlawy A, Origa R, Elalfy M, Kiliç Y, Perrotta S, Karakas Z, **Viprakasit V**, Habr D, Constantinovici N, Shen J, Porter JB;

- HYPERION Investigators. Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. *Blood*. 2015; 125(25):3868-77.
20. Pairash Saiviroonporn, **Vip Viprakasit**, Rungroj Krittayaphong & John C. Wood. Improved T2\* assessments in liver iron overload by 1D and 2D fuzzy c-mean clustering. *BMC Med Imaging*. 2015; 15(1):52. doi: 10.1186/s12880-015-0097-5.
  21. Maria Domenica Cappellini, John B Porter, Khaled M Musallam, Antonis Kattamis, **Vip Viprakasit**, Renzo Galanello and Ali T Taher. A new disease severity scoring system for patients with non-transfusion-dependent Thalassemia. *Eur J Intern Med*. 2016; 28:91-6.
  22. Kamol Phuakpet, Klebsabi Sanpakit, Natsawee Vathana, Chayamol Takpradit, Kunkanya Chokephaibulkit, **Vip Viprakasit**. Hemophagocytic lymphohistiocytosis following dengue hemorrhagic fever in Hb H/Hb Constant Spring patient. *Pediatr Int*. 2015; 57(4):763-5.
  23. Yesim Aydinok, John B Porter, Antonio Piga, Mohsen El-Alfy, Amal El-Beshlawy, Yurdanur Kiliç, **Vip Viprakasit**, Akif Yesilipek, Dany Habr, Erhard Quebe-Fehling and Dudley J Pennell. Prevalence and Distribution of Iron Overload in Patients with Transfusion-dependent Anemias Differs across Geographic Regions: Results from the CORDELIA Study. *Eur J Haematol* 2014; Nov 24. doi: 10.1111/ejh.12487.
  24. JB Porter, M El-Alfy, **V Viprakasit**, S Giraudier, LL Chan, Y Lai, A El-Ali, N Martin and MD Cappellini. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. *Eur J Haematol* 2015; Feb 18. doi: 10.1111/ejh.12540. [Epub ahead of print]
  25. Ali T. Taher, Ali Radwan, **Vip Viprakasit\***. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. *Vox Sang*. 2015; 108(1):1-10
  26. Taher A, Cohen A, Cappellini MD, Porter J, **Viprakasit V**; editor. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Nicosia, Cyprus: Thalassaemia International Federation; 2014.
  27. **Vip Viprakasit\***, Paul Tyan, Sarayuth Rodmai, Ali T. Taher. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. *Orphanet J Rare Dis*. 2014; 30; 9(1):131.
  28. **Vip Viprakasit\***, Supachai Ekwattanakit, Suchada Riolueang, Nipon Chalaow, Chris Fisher, Karen Lower, Hitoshi Kanno, Kalaya Tachavanich, Sasithorn Bejrachandra, Jariya Saipin, Monthana Juntharaniyom, Klebsabi Sanpakit, Voravarn S. Tanphaichitr, Richard Gibbons, Sjaak Philipsen, and Douglas R. Higgs. Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. *Blood* 2014; 123(10):1586-95.
  29. Pairunyar Nakavachara, Jalaporn Pooliam, Linda Weerakulwattana, Pornpimol Kiattisakthavee, Katharee Chaichanwattanakul, Racahnee Manorompatarasarn, Kulkanya Chokephaibulkit & **Vip Viprakasit**. A Normal Reference of Bone Mineral Density

- (BMD) measured by Dual Energy X-ray Absorptiometry in Healthy Thai Children and Adolescents Aged 5-18 Years: A New Reference for Southeast Asian Populations. *PLOS ONE* 2014; 9(5):e97218. doi: 10.1371/journal.pone.0097218. e Collection 2014.
30. Ali T Taher, John B Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Raffaella Origa, Zeynep Karakas, Dany Habr, Zewen Zhu and M Domenica Cappellini. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. *Br J Haematol.* 2015; 168(2):284-90.
  31. Ali T Taher, John B Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Raffaella Origa, Zeynep Karakas, Dany Habr, Zewen Zhu and M Domenica Cappellini. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. *Eur J Haematol.* 2014; 92(6):521-6.
  32. Maria Domenica Cappellini, **Vip Viprakasit** and Ali T Taher. An overview of current treatment strategies for  $\beta$ -thalassemia. *Expert Opinion on Orphan Drug* 2014; 2 (7): 665-679.
  33. **Vip Viprakasit**, Sarayuth Rodmai, Somdet Srichairatanakool. Deferiprone for transfusional iron overload and its roles in developing countries. *Expert Opinion on Orphan Drug* 2014; in press. *Expert Opinion on Orphan Drugs.* 2014; 2 (2): 189-200.
  34. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; **CORDELIA study investigators**. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in  $\beta$ -thalassemia major (CORDELIA). *Blood.* 2014; 123(10): 1447-54.
  35. Yesim Aydinok, Antonis Kattamis, **Vip Viprakasit**. Current approach to iron chelation in children. *Br J Haematol* 2014; 165(6):745-55.
  36. **Vip Viprakasit\***, Supachai Ekwattanakit, Nipon Chalaow, Suchada Riolueang, Sirirat Wijit, Porntep Tanyut, Rapeepun Shompoopueng, Nunthawut Chat-Uthai, Kalaya Tachavanich. Clinical presentation and molecular identification of four uncommon  $\alpha$ -globin variants in Thailand: initiation codon mutation of  $\alpha 2$ -globin gene (HBA2:c.1delA), donor splice site mutation of  $\alpha 1$ -globin gene (IVSI-1, HBA1:c.95+1G>A), Hemoglobin Queens Park/Chao Pra Ya (HBA1:c.98T>A) and Hemoglobin Westmead (HBA2:c.369C>G). *Acta Haematologica*; 2014; 131: 88-94.
  37. Ali T. Taher, Khaled M. Musallam, **Vip Viprakasit**, John B. Porter and Maria Domenica Cappellini. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo. *Blood Cell Molecules and Diseases* 2014; 52(2-3): 88-90.
  38. Archwin Tanphaichitr, Thisarat Kusuwan, Siriporn Limviriyakul, Suvajana Atipas, Tuangrat Sangpraypan, Voravarn S Tanphaichitr, and **Vip Viprakasit\***. Incidence of ototoxicity in pediatric patients with Transfusion Dependent Thalassemia (TDT) who are



- less well-chelated by mono- and combined therapy of iron chelating agents. *Hemoglobin* 2014; 38(5):345-50.
39. Bunchoo Pongtanakul, Kleesabai Sanpakit, Viroj Chongkolwatana & **Vip Viprakasit\***, Normal cognitive functioning in a patient with Hb Bart's hydrops successfully cured by hematopoietic stem cell transplantation. *Bone Marrow Transplantation*; 2014; 49(1):155-6.
  40. Kleesabai Sanpakit & **Vip Viprakasit\*** Variable Genotype-Phenotype Correlations in patients with a rare nondeletional  $\alpha$ -thalassemia; Hb Pak Num Po (HBA1:c.396\_397insT). *Journal Pediatric Hematol Oncol* 2014; 36(3): e185-9.
  41. Punyanuch Pornpanich, Waraporn Glomglao, Suchada Riolueang, Yaowapa Sukontharangsri, Sangkae Chamnanvanakij, Kitti Torcharus & **Vip Viprakasit.\*** Diagnostic applications of an economical newborn screening program using isoelectric focusing (IEF) on dry blood spot for determining  $\alpha$ -thalassemia carriers, HbH and Hb E disorders. *Ann Clin Biochem* 2014; 51(Pt 2):237-47.
  42. Taher A, Vichinsky E, Musallam K, Cappellini MD, **Viprakasit V**; Weatherall D, editor. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation; 2013.
  43. **Vip Viprakasit** Alpha-thalassaemia: From Clinical and Molecular Diagnosis to Bedside Management. *Hematology Education: the education programme for the annual congress of the European Hematology Association*; 2013; 7(1); 329-338
  44. Nipon Chalaow, Swee Lay Thein & **Vip Viprakasit\*** The 12.6 kb-deletion of the  $\beta$ -globin gene cluster was in fact the known Thai/Vietnam  $(\delta\beta)^0$ -thalassemia commonly found in Southeast Asia. *Haematologica*; 2013; 98(9):e117-8.
  45. Smith GC, Taher A, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, **Viprakasit V**, Elalfy MS, Kattamis A, Habr D, Domokos G, Pennell DJ. Cardiac remodelling associated with deferasirox chelation in thalassaemia major. Submitted to *Journal Cardiac Magnetic Resonance Imaging*; 2013; *in press*
  46. **Vip Viprakasit\***, Chanin Limwongse, Sathein Sukpanichnant, Pornpimol Ruangvutilert, Chompunut Kanjanakorn, Waraporn Glomglao, Monchan Sirikong, Witayakarn Utto and Voravarn S. Tanphaichitr. Problems in determining thalassaemia carrier status in a program for prevention and control of severe thalassaemia syndromes: A lesson from Thailand. *Clin Chem Lab Med*; 2013, 23:1-10.
  47. Pairunyar Nakavachara & **Vip Viprakasit\*** Children with hemoglobin E/ $\beta$ -thalassaemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: A study from Thailand. *Pediatric Blood Cancer*; 2013; 60(10):1683-8.
  48. Pairunyar Nakavachara & **Vip Viprakasit#** Adrenal insufficiency is prevalent in HbE/ $\beta$ -thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement. *Clinical Endocrinology*; 2013; 79(6):776-83.

49. Bunchoo Pongtanakul & **Vip Viprakasit\*** Twice daily dosing of deferasirox significantly improves clinical efficacy in transfusion dependent thalassemias who were inadequate responders to standard once daily dose. *Blood Cell Molecules and Diseases*; 2013; 51(2):96-7.
50. Ali Taher<sup>S</sup>, **Vip Viprakasit<sup>TS\*</sup>**, Khaled M. Musallam, Maria D. Cappellini. Treating iron overload in patients with non-transfusion-dependent thalassemia (NTDT). *Am J Hematol* 2013; 88(5):409-15
51. **Vip Viprakasit\***, Issarang Nuchprayoon, Ampaiwan Chuansumrit, Kitti Torcharus MD, Bunchoo Pongtanakul, Jiraporn Laothamatas, Somdet Srichairatanakool, Julaporn Pooliam, Siriwat Supajitkasem, Prapat Suriyaphol, Voravarn S. Tanphaichitr, Soodsarkorn Tuchinda. Deferiprone (GPO-L-ONE) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multi-centre prospective, single arm, open label, dose escalating Phase III study (GPO-L-ONE; A001) from Thailand. *Am J Hematol*; 2013; 88(4):251-60.
52. Ali Taher, John Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Wei Deng, Dany Habr, Maria Domenica Cappellini. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. *Ann Hematol*; 2013; 92(11):1485-93.
53. Ali Taher, John Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Wei Deng, Dany Habr, Maria Domenica Cappellini. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassaemia (NTDT) patients. *Am J Hematol*; 2013; 88(6):503-6
54. Jaruwat Tritipsombut, Marion Phylipsen, **Vip Viprakasit**, Nipon Chalaow, Kanokwan Sanchaisuriya, Piero C. Giordano, Supan Fucharoen, Cornelis L. Harteveld. A single-tube multiplex gap-PCR for the detection of eight  $\beta$ -globin gene cluster deletions common in Southeast Asia. *Hemoglobin*, 2012; 36(6):571-80.
55. David P. Steenma, **Vip Viprakasit**, Robert A. Kyle and Marc A. Shampo. Prince Wongsadhiraj Snid-Thai Physician and Diplomat. *Mayo Clin Proc.* 2012; 87(11); e93
56. **V Viprakasit\***, N Gattermann, JW Lee, JB Porter, A Taher, D Habr, B Roubert, G Domokos, MD Cappellini. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. *Blood Transfus.* 2012; 12:1-14. doi: 10.2450/2012.0012-12. [Epub ahead of print]
57. Suwannee Phumeetham, Nunthawut Chat-uthai, Manutham Manavathongchai, **Vip Viprakasit\***. Genetic association study of tumor necrosis factor-alpha in sepsis and septic shock in Thai pediatric patients. *Jornal de Pediatria (Rio J)*; 2012; 88(5): 423-9. [Epub ahead of print]

58. Supachai Ekwattanakit, Yuwarat Monteerarat, Suchada Riolueang, Kalaya Tachavanich, and **Vip Viprakasit\*** Association of Xmn I Polymorphism and Hemoglobin E Haplotypes on Post-natal Gamma Globin Gene Expression in Homozygous Hemoglobin E. *Advances Hematol*; 2012:528075. Epub 2012 Sep 19.
59. Pairash Saiviroonporn, **Vip Viprakasit,\*** Keebsabi Sanpakit, John C. Wood, Rungroch Krittayaphong Inter-site validations of the pixel-wise method for liver R2\* analysis in transfusion-dependent thalassemia patients to provide more accessibility to technology in a developing country. *Hematol/Oncol & Stem Cell*; 2012;5 (2):91-5.
60. Ali Taher, John Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Wei Deng, Dany Habr, Maria Domenica Cappellini. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomised, double-blind, placebo-controlled study. *Blood*; 2012; 2;120(5):970-7. Epub 2012 May 15.
61. Peter Horby, Chiea C. Khor, Annette Fox, Le Q. Mai, Surakameth Mahasirimongkol, Pham Q. Thai, Nuanjun Wichukchinda, Nguyen T. Yen, Sukanya Wattanapokayakit, Nusara Satproedprai, Luong K. Lan, **Vip Viprakasit**, Sonia Davila, Jeremy Farrar, Tran T. Hien, Tawee Chotpitayasunondh, Sarah J. Dunstan, Nguyen T. Hien, Martin Hibberd. Susceptibility to highly pathogenic avian influenza A/H5N1 associated with interleukin 1 and TRPM8. *PLOS Medicine*; 2012 *in press*
62. Pairash Saiviroonporn, **Vip Viprakasit**, Adisak Maneesai, Noppadol Siritanaratkul, Bunchoo Pongtanakul, John C. Wood, Rungroch Krittayaphong. Inter-site validations of the Pixel-Wise method for cardiac T2\* analysis in transfusion-dependent Thai thalassemia patients. *J Med Assoc Thai*. 2012; 95 Suppl 2:S165-72.
63. Ellis J. Neufeld, Renzo Galanello, **Vip Viprakasit**, Yesim Aydinok, Antonio Piga, Paul Harmatz, Gian Luca Forni, Farrukh T. Shah, Rachael F. Grace, John B. Porter, John C. Wood, Jennifer Peppe, Amber Jones and Hugh Y Rienhoff. Jr. A phase 2, 24 week study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. *Blood* 2012 5;119(14):3263-8. Epub 2012 Jan 17.
64. Dudley Pennell, John Porter, M Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Continued improvement and normalization of myocardial T2\* in patients with  $\beta$  thalassaemia major treated with deferasirox (Exjade<sup>®</sup>) for up to 3 years. *Haematologica*; 2012; 97(6):842-8. Epub 2012 Jan 22.
65. JB Porter, KH Lin, P Beris, GL Forni, A Taher, D Habr, G Domokos, B Roubert, SL Thein; **EPIC study investigators**. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. *Eur J Haematol*. 2011 Oct;87(4):338-48.

66. **Vip Viprakasit**, Hishamshah Ibrahim, Shau-Yin Ha, Joy Ho, Chi Kong Li, Lee Lee Chan, Chang-Fang Chiu, Pranee Sutcharitchan, Bernard Roubert, Hong Ling Xue, Don Bowden and Kai-Hsin Lin. Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: A subanalysis of the EPIC study of deferasirox. *International Journal of Hematology*; 2011: 93(3):319-28.
67. Hugh Young Rienhoff Jr., **Vip Viprakasit**, Lay Tay, Paul Harmatz, Elliott Vichinsky, Deborah Chirnomas, Janet Kwiatkowski, Amy Tapper, William Kramer, John B Porter, and Ellis Neufeld. A phase 1B study pharmacokinetics and pharmacodynamics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. *Haematologica*; 2011: 96(4):521-5.
68. Pairash Saiviroonporn, **Vip Viprakasit**, Thananya Boonyasirinant, Archrob Khuhapinant, John C. Wood, Rungroj Krittayaphong. Comparison of the Region-Based and Pixel-Wise Methods for Cardiac T2\* Analysis in 50 Transfusion-Dependent Thai Thalassemia Patients. *Journal of Comput Assist Tomo*; 2011, 35(3):375-81.
69. Dudley J Pennell, John B Porter, M Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher. Continued improvement in myocardial T2\* over 2 years of deferasirox therapy in thalassemia major patients with cardiac iron overload. *Haematologica*; 2011 Jan;96(1):48-54.
70. Martin J. Law, Karen M. Lower, Hsiao P.J. Voon, Jim R. Hughes, David Garrick, **Vip Viprakasit**, Matthew Mitson, Marco De Gobbi, Marco Marra, Andrew Morris, Aaron Abbott, Steven P. Wilder, Stephen Taylor, Guilherme M. Santos, Joe Cross, Helena Ayyub, Steven Jones, Jiannis Ragoussis, Daniela Rhodes, Ian Dunham, Douglas R. Higgs, & Richard J. Gibbons. ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. *Cell*, 2010 Oct 29;143(3):367-78
71. Vichai Laosombat, **Vip Viprakasit**, Warangkana Thongnoppakun, Supaporn Dissaneevate, Roengsak Leetanaporn, Thirachit Chotsampancharoen, Malai Wongchanchailert, Sudarat Kodchawan, Sarapee Duangchu. Natural history of Southeast Asian Ovalocytosis (SAO) during the first year of life in Thai infants. *Blood Cells Molecules & Diseases*; 2010 Jun 15;45(1):29-32.
72. Yuwarat Monteerarat, Ompreya Suptawiwat, Chompunuch Boonarkart, Mongkol Uiprasetkul, Prasert Auewarakul & **VipViprakasit\***. Inhibition of H5N1 highly pathogenic influenza virus by suppressing a specific sialyltransferase. *Arch Virol*. 2010 Jun;155(6):889-93.
73. Horby P, Sudoyo H, **Viprakasit V**, Fox A, Thai PQ, Yu H, Davila S, Hibberd M, Dunstan SJ, Monteerarat Y, Farrar JJ, Marzuki S, Hien NT. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? *Epidemiol Infect*. 2010 Nov;138(11):1550-8.
74. Cappellini MD, Porter J, Beshlawy A-El, Li CK, Seymour JF, El-Alfy M, Gattermann N, Giraudier S, Lee JK, Chan LL, Lin KH, Rose C, Taher A, Thein SL, **Viprakasit V**, Habr

- D, Domokos G, Hmissi A, and Kattamis, A, on behalf of the EPIC study investigators. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 Patients with transfusion-dependent anemias. *Haematologica* 2010; 95(4):557-66.
75. Dudley Pennell, John B. Porter, Maria Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hisham Ibrahim, **Vip Viprakasit**, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, and Ali Taher. Efficacy of deferasirox in reducing and preventing myocardial siderosis in  $\beta$ -thalassemia. *Blood*. 2010; 115(12):2364-71.
76. Manit Nuinoon, Wattanan Makarasara, Taisei Mushiroda, Orapan Sripichai, Natsuhiko Kumasaka, Atsushi Takahashi, Saovaros Svasti, Thongperm Munkongdee, Surakameth Mahasirimongkol, Chayanon Peerapittayamongkol, **Vip Viprakasit**, Naoyuki Kamatani, Pranee Winichagoon, Michiaki Kubo, Yusuke Nakamura, Suthat Fucharoen. A genome-wide association identified the common genetic variants influences disease severity in  $\beta^0$ -thalassemia/hemoglobin E. *Human Genetics*. 2010; 127(3):303-14.
77. Suthat Fucharoen & **Vip Viprakasit**. Hb H disease: clinical course and disease modifiers. *Hematology Am Soc Hematol Educ Program*. 2009:26-34.
78. **V. Viprakasit\***, C. Lee-Lee, T. Q Thuan Chong, K.-H. Lin and A. Khuhapinant. Iron Chelation Therapy in the Management of Thalassemia: An Asian Perspectives *International Journal of Hematology* 2009; 90: 435-445.
79. Karen M. Lower, Jim R. Hughes, Marco De Gobbi, Shirley Henderson, **Vip Viprakasit**, Chris Fisher, Anne Goriely, Helena Ayyub, Jackie Sloane-Stanley, Douglas Vernimmen, Cordelia Langford, David Garrick, Richard J. Gibbons & Douglas R. Higgs. Adventitious changes in long range gene expression caused by polymorphic structural variation and promoter competition. *Proc Natl Acad Sci U S A*. 2009;106(51):21771-6
80. Chun Yu Lok, Alison T. Merryweather-Clarke, **Vip Viprakasit**, Yingyong Chinthammitr, Somdet Srichairatanakool, Chanin Limwongse, David Oleesky, Anthony J. Robins, John Hudson, Phyu Wai, Anuja Premawardhena, H. Janaka de Silva, Anuradha Dassanayake, Carole McKeown, Maurice Jackson, Rousseau Gama, Nasaim Khan, William Newman, Gurvinder Banait, Andrew Chilton, Isaac Wilson-Morkeh, David J. Weatherall, and Kathryn J. H. Robson Iron overload in the Asian community. *Blood*. 2009; 114(1):20-5.
81. V. Laosombat, **V. Viprakasit**, T. Chotsampancharoen, M. Wongchanchailert, S. Khodchawan, W. Chinchang, B. Sattayasevana. Clinical features and molecular analysis in Thai patients with HbH disease. *Annual of Haematology* 2009; 88(12):1185-92.
82. Kalaya Tachavanich, Wiyakan Utto, Voravarn S Tanphaichitr and **Vip Viprakasit**. Rapid flow cytometric test using eosin-5-maleimide (EMA) for the diagnosis of red cell membrane disorders. *Southeast Asian J Trop Med Public Health*. 2009; 40(3): 570-575.
83. K. Tachavanich, **V. Viprakasit**, P. Pung-Amritt, G. Veerakul, K. Chansing, V.S. Tanphaichitr. Development of a comprehensive red blood cell enzymopathy laboratory in

- Thailand: the study of normal activity in eight erythroenzymes in Thais. *Southeast Asian J Trop Med Public Health*. 2009 Mar; 40(2):317-26.
84. K. Tachavanich, **V. Viprakasit\***, W. Chinchang, W. Glomglao, P. Pung-Amritt, V.S. Tanphaichitr. Clinical and hematological phenotype of homozygous hemoglobin E: revisit of a benign condition with hidden reproductive risk. *Southeast Asian J Trop Med Public Health*. 2009 Mar; 40(2):306-16. \* corresponding author
  85. W. Pariyaprasert, P. Pacharn P, N. Visitsunthorn, K. Chokephaibulkit, K. Sanpakit, **V. Viprakasit**, P. Vichyanond, O. Jirapongsananuruk. Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor. *Asian Pac J Allergy Immunol*. 2008 Mar; 26(1):71-5.
  86. Sookkaseam Khositseth, Apiwan Sirikanerat, Kulruedee Wongbenjarat, Sauwalak Opastirakul, Siri Khoprasert, Ratikorn Peuksungnern, Duangrurdee Wattanasirichaikul, Wanna Thongnoppakhun, **Vip Viprakasit**, Pa-thai Yenchitsomanus. Distal Renal Tubular Acidosis Associated with Anion Exchanger 1 Mutations in Thai Children. *American Journal of Kidney Diseases* 2007; 49(6): 841-850.
  87. Thanyachai Sura, Manisa Busabaratana, Supak Youngcharoen, Raewadee Wisedpanichkij, **Vip Viprakasit** & Objoon Trachoo. Haemoglobin Hope in a northern Thai family: first identification of homozygous haemoglobin Hope associated with haemoglobin H disease. *European Journal of Haematology* 2007; 79(3):251-4.
  88. Thanyachai Sura, Objoon Trachoo, **Vip Viprakasit**, Prin Vathesatogkit, Atchara Tunteeratum, Manisa Busabaratana, Raewadee Wisedpanichkij, Partrapon Isarangkura. Hemoglobin H disease induced by the common SEA deletion and the rare haemoglobin Quong Sze in a Thai female: longitudinal clinical course, molecular characterization, and the development of a PCR/RFLP-based detection method. *Ann Hematology* 2007; 86(9):659-63.
  89. Helene Puehringer, Hossein Najmabadi, Hai-Yang Law, Walter Krugluger, **Vip Viprakasit**, Serge Pissard, Erol Baysal, Ali Taher, Chantal Farra, Amein Al-Ali, Suad Al-Ateeq, Christian Oberkanins. Simultaneous Analysis of Common  $\alpha$ -Thalassemia Point Mutations and Deletions based on Reverse-Hybridization Teststrips. *Clinical Chemical Laboratory Medicine* 2007: 45(5): 605-610.
  90. Worrawut Chinchang and **Vip Viprakasit\***. Further identification of Hb G-Coushatta [ $\beta$  22 (B4) Glu $\rightarrow$ Ala (GAA $\rightarrow$ GCA)] in Thailand by the polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and by the amplification refractory mutation system-polymerase chain reaction. *Hemoglobin* 2007: 31(1): 25-30.
  91. **Vip Viprakasit\*** and Worrawut Chinchang. Two independent origin of Hb Dhonburi (Neapolis) [ $\beta$  126 (H4) Val  $\rightarrow$ Gly]: an electrophoretically silent haemoglobin variant. *Clinica Chimica Acta* 2007: 376(1-2):179-83.
  92. **Vip Viprakasit**, Cornelis L. Harteveld, Helena Ayyub, Jackie S. Stanley, Piero C. Giodano and Douglas R. Higgs. A novel deletion causing  $\alpha$  thalassemia clarifies the

- importance of the major human alpha globin regulatory element. *Blood* 2006: 107(9):3811-2.
93. **Marco De Gobbi<sup>S</sup>, Vip Viprakasit<sup>S</sup>**, Jim Hughes, Chris Fisher, Veronica J Buckle, Helena Ayyub, Richard J Gibbons, Doug Vernimmen, Yuko Yoshinaga, Pieter de Jong, Jan Fang Chen, Edward M Rubin, William G Wood, Don Bowden, Douglas R Higgs. A remote, gain of function regulatory SNP illustrating a novel mechanism for human genetic disease. *Science* 2006: 312(5777):1215-7.
  94. Anirut Pattaragarn, **Vip Viprakasit**, Suroj Supavekin and Achra Sumboonnanonda. Immune-mediated hemolytic anemia in pediatric transplantation. *Pediatric Transplantation* 2006 :10(6): 740-3.
  95. **Vip Viprakasit\***, Worrawut Chinchang, Pipat Chotimarat. Hb Woodville, a rare alpha globin variant, caused by codon 6 mutation of the alpha 1 gene. *European Journal of Hematology*: 2006: 76(1): 79-82.
  96. **Vip Viprakasit\***, Lurlugn Suwanthol, Tuangrath Sangpraypan, Waraporn Glomglaio, Witayakarn Utto and Gavivann Veerakul. Hematological parameters and red blood cell indices in healthy Thai children: A revision for 2005. *J Med Ass Thailand*, 2005: 88 (Suppl 8): S188-96.
  97. Nassawee Vathana, **Vip Viprakasit\***, Klebsabi Sanpakit, Worrawut Chinchang, Gavivann Veerakul and Voravarn S. Tanphaichitr. Clinical phenotypes and molecular diagnosis in a hitherto interaction of Hb E/ $\beta$  thalassemia syndrome ( $\beta^E/\beta^{-31, A.G}$ ). *J Med Ass Thailand*, 2005: 88 (Suppl 8): S66-71.
  98. Bunchoo Pongtanakul, Nattee Narkbunnam, Gavivann Veerakul, Klebsabai Sanpakit, **Vip Viprakasit**, Voravarn S. Tanphaichitr and Vinai Suvatte. Dengue hemorrhagic fever in patients with thalassemia. *J Med Ass Thailand*, 2005: 88 (Suppl 8): S80-5.
  99. A.Premawardhena, C.A. Fisher, N.F. Olivieri, S. de Silva, M. Arambepola, W. Perera, A.O'Donnell, T.E.A. Peto, **V. Viprakasit**, L. Merson, G. Muraca, D.J. Weatherall. Hb E  $\beta$  thalassaemia in Sri Lanka. *Lancet* 2005: 366(9495):1467-70.
  100. **Vip Viprakasit\***, Worrawut Chinchang, Lurlugh Suwanthon and Voravarn S. Tanphaichitr. Common origin of a rare  $\beta$ -globin initiation codon mutation (ATG $\rightarrow$ AGG) in Orientals. *Clinical Laboratory Haematology* 2005: 27(6): 409-15.
  101. Worrawut Chinchang, **Vip Viprakasit\***, Parichat Pung-Amritt, Voravarn S. Tanphaichitr and Pa-thai Yenchitsomanus. Molecular analysis of unknown  $\beta$ -globin gene mutations using polymerase chain reaction-single strand conformation polymorphism technique (PCR-SSCP) and its application in Thai families with  $\beta$ -thalassemias and  $\beta$ -globin variants. *Clinical Biochemistry* 2005: 38(11): 987-96.
  102. Yingyong Chinthammitr, Worrawut Chinchang, Theera Ruchutrakool and **Vip Viprakasit<sup>#</sup>** Identification of a novel signal peptide mutation causes Type-I antithrombin deficiency in Thai patients. *Thrombosis and Haemostasis* 2005: 94 (3): 678-679.

103. **Vip Viprakasit\***, Worrawut Chinchang, Waraporn Glomglao and Voravarn S. Tanphaichitr. An unusual case of Hb H disease associated with  $\alpha^0$  thalassemia ( $--^{SEA}$ ) and a rare initiation codon mutation (ATG→A-G) of the  $\alpha 2$  gene. *Hemoglobin* 2005: 29 (3):235-40.
104. P. Wasant, V. **Viprakasit**, C. Srisomsap, S. Liammongkolkul, P. Ratanarak, A. Sathienkijakanchai, J. Svasti. Genetic Analysis in Thai families with citrullinemia suggesting mutation hotspots of argininosuccinate synthetase. *Southeast Asian Journal of Tropical Medicine and Public Health* 2005: 36 (3): 757-761.
105. Hal Drakesmith, Lisa M Schimanski, Emma Ormerod, Alison T Merryweather-Clarke, **Vip Viprakasit**, Jon P Edwards, Emma Sweetland, Judy M Bastin, Diana Cowley, Yingyong Chinthammitr, Kathryn JH Robson and Alain RM Townsend. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. *Blood* 2005: 106 (3): 1092-1097.
106. Lisa Schimanski, Hal Drakesmith, Alison Merryweather-Clarke, **Vip Viprakasit**, Yingyong Chinthammitr, Emma Sweetland, Judy Bastin, Diana Cowley, Jon Edwards, Kathryn Robson and Alain Townsend. Functional studies on human ferroportin and naturally occurring mutations of the gene, implicated in type IV haemochromatosis. *Blood* 2005: 105 (10): 4096-4102.
107. Vichai Laosombat, Benjamas Sattayasevana, Waricha Janejindamai, **Vip Viprakasit**, Taku Shirakawa, Kaoru Nishiyama and Masafumi Matsuo. Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in the south of Thailand and identification of a novel variant (G6PD Songklanagarind). *Blood Cell Molecules and Diseases* 2005: 34(2): 191-6.
108. Kathryn JH Robson, Alison T Merryweather-Clarke, Estelle Cadet, **Vip Viprakasit**, Monique G Zaahl, Jennifer J Pointon, Jacques Rochette. Recent advance in understanding haemochromatosis: a transition state (invited review) *Journal of Medical Genetics* 2004: 41: 721-730.
109. **Vip Viprakasit\***, Prin Vathesathokit, Worrawut Chinchang, Kalaya Tachavanich, Parichat Pung-Amritt, Pathai Yenchitsomanus, Alison Merryweather-Clarke and Voravarn S. Tanphaichitr. Prevalence of *HFE* mutations among Thai population and its correlation with iron loading in hemoglobin E disorder. *European Journal of Haematology* 2004: 73: 43-49.
110. **Vip Viprakasit\***, Gavivann Veerakul, Kleebsabai Sanpakit, Bunchoo Pongtanakul, Worrawut Chinchang and Voravarn S. Tanphaichitr Homozygous Haemoglobin Constant Spring (Hb CS), an unusual cause of acute intravascular haemolysis in a Thai boy. *Annual of Tropical Pediatrics* 2004: 24, 323-328.
111. **Vip Viprakasit\***, Voravarn S. Tanphaichitr, Worrawut Chinchang, Mitchell J. Weiss and Douglas R. Higgs. Evaluation of Alpha Hemoglobin Stabilizing Protein (AHSP) as a genetic modifier in patients with  $\beta$  thalassemia. *Blood* 2004: 103 (9): 3296-3299.



112. **Vip Viprakasit\*** & Voravarn S. Tanphaichitr. An unusual phenotype of Hb EE with Hb H disease: a pitfall in clinical diagnosis and genetic counseling. *Journal of Pediatrics* 2004; 144 (3): 391-393.
113. **Vip Viprakasit\***, Voravarn S. Tanphaichitr, Gavivann Veerakul, Worrawut Chinchang, Siripan Petrarat, Parichat Pung-Amritt and Douglas R. Higgs. Hb Pak Num Po, a novel  $\alpha$ -1 gene mutation in association with  $\alpha^0$  thalassaemia causes transfusion dependent Hb H disease. *American Journal of Hematology* 2004; 75: 157-163.
114. **Vip Viprakasit\***, Worrawut Chinchang, Parichat Pung-Amritt and Voravarn S. Tanphaichitr. Identification of Hb Q-India in Thailand. *Hematology* 2004; 9 (2): 151-155.
115. David P. Steenma, **Vip Viprakasit**, Alex Hendrick, David K. Goff, Jeoanne Leach, Richard J. Gibbons & Douglas R. Higgs. Deletion of the  $\alpha$  globin gene cluster as a cause of acquired  $\alpha$  thalassaemia in myelodysplastic syndrome (ATMDS). *Blood* 2004; 103(4):1518-1520.
116. **Vip Viprakasit\***, Helena Ayyub and Alison May. Dinucleotide deletion in a  $-\alpha^{3.7}$  allele as a cause of more severe  $\alpha^+$  thalassaemia. *European Journal of Haematology*, 2003; 71: 133-136.
117. Alison T. Merryweather-Clarke, Estelle Cadet, Adrian Bomford, Dominique Capron, **Vip Viprakasit**, Anne Miller, PJ McHugh, Jane Collier, Roger Chapman, Jennifer J Pointon, Victoria LC Wimhurst, Voravarn Tanphaichitr, Jacques Rochette & Kathryn JH Robson. Digenic inheritance of mutations in *HAMP* and *HFE* result in different types of haemochromatosis. *Human Molecular Genetics*, 2003; 12(17): 2241-7.
118. **Vip Viprakasit**, Alexa M.J. Kidd, Helena Ayyub and Douglas R. Higgs. *De novo* deletion within the telomeric region flanking the human  $\alpha$  globin locus as a cause of  $\alpha$  thalassaemia. *British Journal of Haematology*, 2003; 120: 867-875.
119. Jenny J Pointon, **Vip Viprakasit**, Kathie Milles, Alison T. Merryweather-Clarke and Kathryn J. Robson. Hemochromatosis gene (HFE) mutations in South East Asia: a potential for iron loading. *Blood Cell Molecules and Diseases*, 2003; 30: 302-306.
120. Voravarn S. Tanphaichitr, **Vip Viprakasit\***, Gavivann Veerakul, Kleebsabai Sanpakit and Panatsaya Tientadakul. Homozygous Hemoglobin Tak Causes Symptomatic Secondary Polycythemia in a Thai Boy. *Journal of Pediatric Hematology-Oncology*, 2003; 25: 261-5.
121. **Vip Viprakasit**, Sarah Green, Sarah Height, Helena Ayyub and Douglas R. Higgs. Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of  $\alpha$  thalassaemia ( $-\text{MED}/\alpha^{\text{TSaudia}}$ ). *British Journal of Haematology*, 2002; 117: 759-762.
122. **Vip Viprakasit\***, Suthida Kankirawatana, Pravit Akarasereenont, Kritvikrom Durongpisitkul, Sirikul Chotewuttakorn and Voravarn S. Tanphaichitr. Baseline levels of

- plasma endothelin-1 (ET-1) and changes during transfusion in thalassemic patients. *American Journal of Hematology*, 2002: 70:260-2.
123. **Vip Viprakasit\***, Aranya Wiriyasateinkul, Benjamas Sattayasevana, Kathie Milles and Vichai Laosombat. Molecular Characterization and Clinical Phenotypes of Hb G-Makassar ( $\beta_6$  (A3) Glu $\rightarrow$ Ala) in heterozygosity and compound heterozygosity with  $\beta^0$  thalassemia. *Hemoglobin*, 2002: 26 (3): 245-253.
  124. **Vip Viprakasit\***, Parichat Pung-Amritt, Lirlugh Suwanthon, Kevin Clark and Voravarn S. Tanphaichitr. Complex interactions of  $\delta\beta$  hybrid haemoglobin (Hb Lepore-Hollandia), Hb E (b26 G>A) and  $\alpha^+$  thalassaemia in a Thai family. *European Journal of Haematology*, 2002: 68: 107-111.
  125. **Vip Viprakasit\*** and Voravarn S. Tanphaichitr. Compound Heterozygosity of  $\alpha^0$  thalassaemia (--THAI deletion) and Haemoglobin Constant Spring causes severe Haemoglobin H disease. *Hemoglobin*, 2002; 26 (2): 155-162.
  126. **Vip Viprakasit\***, Voravarn S. Tanphaichitr, Parichat Pung-Amritt, Siripan Petrarat, Lirlughn Suwantol, Chris Fisher and Douglas R. Higgs. Clinical phenotypes and molecular characterisation of Hb H-Pakse' disease. *Haematologica*, 2002; 87:117-25.
  127. **Vip Viprakasit\***, Galaya Tachavanich, Lirlughn Suwantol, Parichat Pung-Amritt, Worrawut Chinchang and Voravarn S. Tanphaichitr. Allele Related Mutation Specific-Polymerase Chain Reaction (ARMS-PCR) for rapid diagnosis of Hb New York (beta 113(G15) Val  $\rightarrow$  Glu,  $\beta^{CD113 GTG\_GAG}$ ). *J Med Ass Thailand*, 2002: 85:supplement 2: S558-563.
  128. Voravarn S. Tanphaichitr, Rachaneekorn Chonlasin, Lirlughn Suwantol, Parichat Pung-Amritt, Galaya Tachavanich, Suthee Yodsan and **Vip Viprakasit**. Effect of Red Blood Cell Glucose-6-Phosphate Dehydrogenase Deficiency on Patients with Dengue Hemorrhagic Fever. *J Med Ass Thailand*, 2002: 85: 85:supplement 2: S522-529.
  129. **Vip Viprakasit**, Richard J. Gibbons, Bernard C. Broughton, John L. Tolmie, Donald Brown, Peter Lunt, Robin M. Winter, Stefano Marinoni, Miria Stefanini, Louise Brueton, Alan R. Lehmann & Douglas R. Higgs. Mutations in the general transcription factor TFIID result in  $\beta$  thalassaemia in individuals with trichothiodystrophy *Human Molecular Genetics*, 2001; 15: 10 (24) 2797-2802.
  130. **Viprakasit V\*** and Tanphaichitr VS. Recurrent A 353 V mutation in a Thai family with X-linked dyskeratosis congenita. *Haematologica*, 2001; 86(8): 871-2.
  131. **Viprakasit V\***, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P, and Suvatte V. Linear Growth in Homozygous  $\beta$ -thalassaemia and  $\beta$ -thalassaemia/Hemoglobin E patients under different treatment regimen *J Med Ass Thailand*, 2001; 84:942-947.

## PAPERS UNDER PREPARATION

Kritvikrom Durongpisitkul, Voravarn S. Tanphaichitr and **Vip Viprakasit\***. Cardiac Complications in Paediatric Patients with Haemoglobin E Thalassaemia.

Yuwarat. Monteerarat, Orathai Piboonpocanun, Kleebsabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond, **Vip Viprakasit**. Identification of a novel *IL7RA* mutation (444\_450 AIns) caused reduction in CD 127 expression on T cells.

Yuwarat. Monteerarat, Orathai Piboonpocanun and **Vip Viprakasit**. A novel molecular based technique to detect recurrent *IL2R* gene mutation in a prenatal diagnosis setting.

Manutham Manavathongchai, Dussadee Akaramethathip, Payon Boonyarittipong, **Vip Viprakasit**. Incidence and risk factors complications in central venous catheterization in pediatric patients. Submitted to *Journal of Medical Association of Thailand* :

**Vip Viprakasit\***, Worrawut Chinchang, Voravarn S. Tanphaichitr and Douglas R. Higgs. Natural history of childhood Hb H disease in Southeast Asia. Submitted to *Pediatric Blood*

**Vip Viprakasit\*** and Worrawut Chinchang. Heterogeneous spectrum of molecular basis of  $\alpha$ -thalassaemia in Thailand; a genotype analysis in 500 patients with Hb H disease. Submitted to *Human Mutation*.

**Vip Viprakasit\***, Lerlugsn Suwantol and Worrawut Chinchang. An analysis toward better genetic counseling in pediatric patients with Hb E/ $\beta$  thalassaemia. Submitted to *Pediatric Hematology Oncology*

**Vip Viprakasit\***, Pojchong Chotiyarnwong, Worrawut Chinchang and Yingyong Chinthammitr. Is the novel antithrombin mutation (antithrombin-Siriraj) an inherited risk factor in Thai population. Submitted to *Journal of Human Genetics*

## PUBLICATIONS IN NATIONAL JOURNALS

1. Thisarat Kusuwan, Lakha Pangnukroh, Wanida Leekamnerdthai, Tuangrat Sangpraypan<sup>2</sup> & **Vip Viprakasit**. Analysis of treatment compliance and related health and social determining factors in Thai thalassaemia patients under long-term deferoxamine administration. *Siriraj Nursing Journal*, 2008; 2(1); 1-14.
2. Tuangrath Sanpraypan, Niltita Sripiboonkit, Kalaya Tachavanich, Lurlugn Suwantol & **Vip Viprakasit\***. Patients' satisfaction on services provided at pediatric regular transfusion clinic, Siriraj hospital. *Institute of Chest Medical Journal*, 2009;
3. Manutham Manavathongchai, Payon Boonyarittipong, Ariya Sanguanwongthong, Kannikar Booranavanich, Siviruk Karnjanabad & **Vip Viprakasit**. Incidence and risk factors of post-phototherapy neonatal bilirubin rebound. *Vajira Medical Journal*, 2007;51(1); 25-31.
4. Waraporn Glomglao, Witayakarn Utto, Wilaiwan Chansing, Parichat Pung-Amritt, Worrawut Chinchang and **Vip Viprakasit**. Application of the Multiplex GAP Polymerase

Chain Reaction (PCR) Analysis for 7 Common Deletional  $\alpha$ -Thalassemias Detection in Routine Laboratory Service *Journal of Medical Technology and Physical Therapy*, 2006; 18: 43-50.

5. **Vip Viprakasit**. Hemoglobin Pak Num Po (Hb PNP), a novel unorthodox  $\alpha$  hemoglobin variant causing severe form of  $\alpha$  thalassemia. *Siriraj Med J*, 2005; 57: 477-8.
6. Kleesabai S. Sanpakit, Voravarn S. Tanphaichitr, Gavivann Veerakul, Bunchoo Pongtanakul, **Vip Viprakasit** and Parichat Pung-Amritt. Hereditary methemoglobinemia due to cytochrome b5 reductase deficiency *Thai Journal of Hematology and Transfusion Medicine* 2004; 14: 281-7.
7. Suthida Kankirawatana, Vinai Suwattee, Chularattana Mahasanthana, Voravarn S. Tanphaichitr, Gavivann Veerakul, **Vip Viprakasit**. Management for pediatric patients with severe aplastic anemia. *Siriraj Hospital Gazzette*, 1999; 51; 3; 180-191.
8. **Vip Viprakasit** and Voravarn S. Tanphaichitr. Molecular basis of alpha thalassemia. *Thai Journal of Hematology and Transfusion Medicine*, 1999; 9: 219-230.
9. **Vip Viprakasit** and Panja Gulapong. Reactive haemophagocytic syndrome in children. *Chiang Mai University, Faculty of Medicine Bulletin*, 1997; 36 Suppl.
10. **Vip Viprakasit** and Torphong Sanguansermisri Prevention and control of severe thalassemia syndrome: Chiang Mai Strategy. *Chiang Mai University, Faculty of Medicine Bulletin* 1997; 36 Suppl.

## PROCEEDINGS OF INTERNATION MEETINGS AND CONFERENCES

1. Ali T Taher, M Domenica Cappellini, Yesim Aydinok, John B Porter, Zeynep Karakas, **Vip Viprakasit**, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro and Yong-Rong Lai. Optimizing iron chelation therapy with deferasirox for non-transfusion-dependent thalassemia patients: 1-year results from the Phase IV, open-label THETIS study. (Presented as a poster presentation in the 56th Annual meeting of the American Society of Hematology, December 7-11, 2015, Orlando, USA).
2. M Domenica Cappellini, **Vip Viprakasit**, Yesim Aydinok, John B Porter, Yong-Rong Lai, Noppadol Siritanaratkul, Zeynep Karakas, Antonis Kattamis, Candace Wang, Zewen Zhu, Felicity Schaefer and Ali T Taher. Efficacy and safety of deferasirox across underlying non-transfusion-dependent thalassemia syndromes: 1-year results from the THETIS study. (Presented as a poster presentation in the 56th Annual meeting of the American Society of Hematology, December 7-11, 2015, Orlando, USA).
3. Bunchoo Pongtanakul & **Vip Viprakasit**. Long term efficacy, safety and tolerability of twice daily dosing of deferasirox in transfusion dependent thalassemias who were unresponsiveness to standard once daily. (Presented as a poster presentation in the 56th Annual meeting of the American Society of Hematology, December 7-11, 2015, Orlando, USA).
4. **Vip Viprakasit**. Challenges in managing thalassemia. Symposium 9: Pediatric Haematology. The Current Science of Haematology. Plenary lecture, Proceeding Book for programme and abstract for The Xth Malaysian National Haematology Scientific Meeting. April 26-28, 2013, Georgetown, Penang, Malaysia.
5. **Vip Viprakasit**. Non-transfusion dependent thalassemia (NTDT): complications due to iron overload and its management. challenges. Plenary lecture, The Current Science of Haematology. Invited speaker, Proceeding Book for programme and abstract for The Xth Malaysian National Haematology Scientific Meeting. April 26-28, 2013, Georgetown, Penang, Malaysia.
6. **Vip Viprakasit**, Sarayuth Rodmai, Suchada Riolueang, Nipon Chalaow, Sirirat Wijit, Porntep Tanyut, Julaporn Pooliam, Bunchoo Pongtanakul. Pharmacogenetic study of UGT1A1 and UGT1A6 polymorphisms and haplotypes in transfusion dependent thalassaemia patients revealed a counterbalance effect between two UGT isoforms on determining clinical response to once daily dose of deferasirox therapy. (Presented as a poster presentation in the 5th Congress of the International, Bioiron Society (IBIS), Biennial World Meeting (Bioiron 2013), April 14-18, 2013, University College London, London, UK).
7. **Vip Viprakasit**, Suchada Riolueang, Sirirat Wijit, Porntep Tanyut, Sarayuth Rodmai, Nipon Chalaow, Julaporn Pooliam, Bunchoo Pongtanakul. Determination of UGT1A1 and UGT1A6 genetic polymorphisms on clinical response to deferiprone monotherapy from a 1-year multi-centre prospective, single arm, open label, dose escalating Phase III pediatric study (GPO-L-ONE; A001) from Thailand. (Presented as a poster presentation

in the 5th Congress of the International, Bioiron Society (IBIS), Biennial World Meeting (Bioiron 2013), April 14-18, 2013, University College London, London, UK).

8. **Vip Viprakasit**, Nipon Chalaow, Sarayuth Rodmai, Suchada Riolueang, Sirirat Wijit, Portep Tanyut, Waraporn Glomglao, Kotpichon Chansing, Kalaya Tachawanich, Wiyakarn Utto, Wilaslak Tanongsaksakul, Somdet Srchairatanakool. Variable degree of mean cell volume (MCV) and mean corpuscular hemoglobin (MCH) in hemoglobin E carriers is determined by a common TMPRSS6 variant (RS855791) in Thai population. (Presented as a poster presentation in the 5th Congress of the International, Bioiron Society (IBIS), Biennial World Meeting (Bioiron 2013), April 14-18, 2013, University College London, London, UK).
9. Ali Taher, John Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Dany Habr, Zewen Zhu, M. Domenica Cappellini. The safety profile of deferasirox remains consistent as non-transfusion-dependent thalassemia patients approach the target liver iron concentration of < 3 mg Fe/g dw for interrupting chelation. (Presented as an oral presentation in the 18th European Haematology Association (EHA), June 13-16, 2013, Stockholm, Sweden).
10. Ali Taher, John Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Dany Habr, Zewen Zhu, M. Domenica Cappellini. Serum ferritin for predicting clinical relevant LIC thresholds to guide management of patients with non-transfusion dependent thalassemia treated with deferasirox: THALASSA study extension analysis. (Presented as an oral presentation in the 18th European Haematology Association (EHA), June 13-16, 2013, Stockholm, Sweden).
11. Yesim Aydinok, Renzo Galanello, **Vip Viprakasit**, Antonio Piga, Paul Harmatz, Gian Forni, Farrukh Shah, Rachael Grace, John Porter, Elliott Vichinsky, John Wood, Suba Krishnan, Pinggao Zhang, Walid Abi-Saab, Hugh Rienhoff Jr, Ellis Neufeld. The safety, tolerability and efficacy of FBS0701, an iron chelator in clinical development for transfusional iron overload: data from 72 weeks of treatment. (Presented as an oral presentation in the 18th European Haematology Association (EHA), June 13-16, 2013, Stockholm, Sweden). *Haematologica* 2013; 98(s1); 487-8
12. John B Porter, Mohsen Elalfy, **Vip Viprakasit**, Stéphane Giraudier, Lee Lee Chan, Yongrong Lai, Ali El-Ali, Nicolas Martin, and M Domenica Cappellini. Serum ferritin, labile plasma iron and transferrin saturation: comparison between underlying anemias with transfusional iron overload before and after treatment with deferasirox. (Presented as a poster presentation in the 53th Annual meeting of the American Society of Hematology, December 7-11, 2012, Atlanta, USA).
13. Ali T Taher, John B Porter, **Vip Viprakasit**, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Zewen Zhu and M Domenica Cappellini. Deferasirox continues to reduce iron overload in non-transfusion dependent thalassemia: a one-year, open-label extension to a randomized, double-blind, placebo-

controlled study. (Presented as a poster presentation in the 53th Annual meeting of the American Society of Hematology, December 7-11, 2012, Atlanta, USA).

14. Bunchoo Pongtanakul & **Vip Viprakasit**. Twice daily dosing of deferasirox significantly improves clinical efficacy in transfusion dependent thalassemias who were inadequate responders to standard once daily dose. (Presented as a poster presentation in the 53th Annual meeting of the American Society of Hematology, December 7-11, 2012, Atlanta, USA).
15. D J Pennell, J B Porter, A Piga, M El-Alfy, A El-Beshlawy, Y Kiliç, **V Viprakasit**, A Yesilipek, T Lawniczek, D Habr, M Weisskopf, Y Zhang and Y Aydinok. Prevalence of cardiac iron overload in patients with transfusion-dependent anemia; data from the randomized, active-controlled deferasirox CORDELIA trial. The 3rd Pan-European Conference on Haemoglobinopathies and Rare anemias, October 24-26, 2012, Limassol, Cyprus. (poster presentation)
16. AT Taher, JB Porter, **V Viprakasit**, A Kattamis, S Chuncharunee, P Sutcharitchan, N Siritanaratkul, R Galanello, Z Karakas, T Lawniczek, D Habr, J Ros, Z Zhu and MD Cappellini. Deferasirox (Exjade®) dose escalation achieves greater reductions in iron overload in non-transfusional-dependent thalassemia patients: 1-year results from the THALASSA study. The 3rd Pan-European Conference on Haemoglobinopathies and Rare anemias, October 24-26, 2012, Limassol, Cyprus. (poster presentation)
17. AT Taher, JB Porter, **V Viprakasit**, A Kattamis, S Chuncharunee, P Sutcharitchan, N Siritanaratkul, R Galanello, Z Karakas, T Lawniczek, D Habr, J Ros, Z Zhu and MD Cappellini. Use of serum ferritin measurements to estimate liver iron concentration in non-transfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study. The 3rd Pan-European Conference on Haemoglobinopathies and Rare anemias, October 24-26, 2012, Limassol, Cyprus. (poster presentation).
18. AT Taher, JB Porter, **V Viprakasit**, A Kattamis, S Chuncharunee, P Sutcharitchan, N Siritanaratkul, R Galanello, Z Karakas, T Lawniczek, D Habr, J Ros, Z Zhu and MD Cappellini. Consistency of liver iron reduction with deferasirox (EXJADE®) across subgroups of non-transfusion-dependent thalassemia patients from the 1-year THALASSA study. The 3rd Pan-European Conference on Haemoglobinopathies and Rare anemias, October 24-26, 2012, Limassol, Cyprus. (poster presentation).
19. Luke Forster, **Vip Viprakasit**, Worrawut Chinchang, Suchada Riolueang, Talal Qadah, Jill Finlayson, and Reza Ghassemifar. In vitro analysis of the HBB:c.129delT beta thalassaemia mutation (Haemoglobin Yala). Presented as a poster presentation in the HAA meeting 2012.
20. Pairunyar Nakavachara, **Vip Viprakasit**. Adrenal insufficiency is commonly present in Pediatric Patients with Non-Transfusion Dependent Thalassemia (NTDT) due to Hb E/ $\beta$  thalassemia. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)

21. Portep Tanyut, Nuntawut Chat-Uthai, Tuangsit Wataganara, Pornpimol Ruengwuttillert , **Vip Viprakasit**. Rapid detection of common alpha-thalassemia deletions found in Asia using a single-step multiplex real-time PCR analysis followed by a melting curve analysis. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
22. Sirirat Wijit, Bunchoo Pongtanakul, Kleebsabi Sanpakit, Suchada Riolueang, Nipon Chalaow, Wiyakan Utto, Nuntawut Chat-Uthai, **Vip Viprakasit**. Severe Hyperbilirubinemia with Transaminitis in a Patient with Hb H-CS due to Coinheritance of Gilbert's Syndrome: The First Case Report in Thailand. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
23. Narawadee Rujanapun, Duangkamol Phummiratch, Sasitorn Aueviriyavit, Suchada Riolueang, Nipon Chalaow, Rawiwan Maniratanachote, **Vip Viprakasit**. *In vitro* toxicological effects of silver nanoparticles in human hematological cell lines. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
24. Nipon Chalaow, Marion Phylipsen, Suchada Riolueang, Nunthawut Chat-Uthai, Corneilis Hartevelde **Vip Viprakasit**. Molecular Characterization of SEA-type deletion of the Beta-globin Gene Cluster using Combined Multiplex Ligation dependent Probe Amplification (MLPA) and Array Comparative Genomic Hybridization (a-CGH). The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
25. Suchada Riolueang, Waraporn Glomglao, Kalaya Techawanich, Kotpichon Chansing, Nipon Chalaow, Supachai Ekwattanakit , **Vip Viprakasit**. The Origin of Sickle Cell Disease (SCD) in Thailand. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
26. Nipon Chalaow, Suchada Riolueang, Chompunut Karnjanakorn, Chanin Limwongse **Vip Viprakasit**. Molecular Characterization of Postnatal Expression of Gamma Globin Genes due to Deletions involved the  $\beta$  globin gene cluster in Thailand. The 3<sup>rd</sup> Asia Pacific Iron Academy (APIA) Conference, 3-4 November 2012, Taipei Taiwan. (poster presentation)
27. **Vip Viprakasit**. Tissue-iron monitoring: A critical step for thalassemia management in 2012. Invited speaker. Optimising Quality of life, Souvenir programme and book of abstracts. 5<sup>th</sup> National Thalassemia Seminar. October 6-7, 2013, Sunway Putra Hotel, Kuala Lumpur, Malaysia.
28. **Vip Viprakasit**. Genotype-phenotype correlation in Thalassemia: What's new. Invited speaker. Optimising Quality of life, Souvenir programme and book of abstracts. 5<sup>th</sup> National Thalassemia Seminar. October 6-7, 2013, Sunway Putra Hotel, Kuala Lumpur, Malaysia.
29. **Vip Viprakasit**. Prevention-Prevention-Prevention: The only means to tackle national health burden related to thalassemia, a lesson from Thailand. Invited speaker. Optimising Quality of life, Souvenir programme and book of abstracts. 5<sup>th</sup> National Thalassemia Seminar. October 6-7, 2013, Sunway Putra Hotel, Kuala Lumpur, Malaysia.



30. **Vip Viprakasit.** Hb E syndromes: How to diagnose and manage these patients. Invited speaker. Proceeding Book for programme and abstract for the 2<sup>nd</sup> ASEAN Federation Haematology Scientific Congress. September 7-8, 2012, Waterfront Conference Centre, Grand Copthorne Waterfront Hotel, Singapore.
31. **Vip Viprakasit.** Novel/rare causes of congenital non-immune hemolytic anemia. Invited speaker. Proceeding Book for programme and abstract for the 2<sup>nd</sup> ASEAN Federation Haematology Scientific Congress. September 7-8, 2012, Waterfront Conference Centre, Grand Copthorne Waterfront Hotel, Singapore.
32. **Vip Viprakasit.** Thalassemia Screening in developing countries: The critical first step for prevention and control for severe thalassemia syndrome. The 6<sup>th</sup> Professor Alendry P. Caviles, Jr. Memorial lecture. Proceeding book for the 42rd Annual Convention Moving forward progress and updates in Hematology and Blood transfusion. The Philippine Society of Hematology and Blood Transfusion. September 2-4, 2013, Crown Plaza Manila, Galleria Hotel, Manila, The Philippines.
33. A Taher, J Porter, **V Viprakasit**, A Kattamis, S Chuncharunee, P Sutcharitchan, N Siritanaratkul, R Galanello, Z Karakas, T Lawniczek, D Habr, J Ros, Y Zhang, D Cappellini. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion dependent thalassemia patients: analysis from the 1 year THALASSA study. (Presented as a poster presentation in the 17th European Haematology Association (EHA), June 14-17, 2012, Amsterdam, The Netherlands).
34. D Pennell, J Porter, A Piga, M El-Alfy, A El-Beshlawy, Y Kilinç, **V Viprakasit**, A Yesilipek, T Lawniczek, D Habr, M Weisskopf, Y Zhang, Y Aydinok. Prevalence of cardiac iron overload in patients with transfusion-dependent anemias: data from the randomized, active-controlled deferasirox CORDELIA trial. (Presented as a poster presentation in the 17th European Haematology Association (EHA), June 14-17, 2012, Amsterdam, The Netherlands).
35. A Taher, J Porter, **V Viprakasit**, A Kattamis, S Chuncharunee, P Sutcharitchan, N Siritanaratkul, R Galanello, Z Karakas, T Lawniczek, D Habr, J Ros, Y Zhang, D Cappellini. Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox: results from the 1-year THALASSA study. (Presented as a poster presentation in the 17th European Haematology Association (EHA), June 14-17, 2012, Amsterdam, The Netherlands).
36. R Galanello, Y Aydinok, A Piga, GL Forni, **V Viprakasit**, P Harmatz, F Shah, R Grace, E Vichinsky, J Wood, J Peppe, A Jones, HY Rienhoff Jr., E Neufeld. A 48 week phase 2 study of the safety, tolerability and efficacy of FBS0701, a novel iron chelator for treatment of transfusional iron overload. (Presented as an oral presentation in the 17th European Haematology Association (EHA), June 14-17, 2012, Amsterdam, The Netherlands).
37. John C. Wood, Hugh Rienhof, Renzo Galanello, Yesim Aydinok, **Vip Viprakasit**, Antonio Piga, Gian Luca Forni, Paul Harmatz, MD, Farrukh T Shah, Rachael F. Grace, John B. Porter, Jennifer Peppe, Amber Jones, and Ellis Neufeld. Disparities between two

- common MRI metrics of liver iron concentration in transfusional siderosis. Ancillary Study from CTP-04: A Phase 2 trial of FBS0701. (Presented as a poster presentation in the 53th Annual meeting of the American Society of Hematology, December 9-11, 2011, San Diego, USA).
38. Ali T Taher, John B. Porter, **Vip Viprakasit**, MD, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppodol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr and M. Domenica Cappellini. Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study (Presented as an oral presentation in the 53th Annual meeting of the American Society of Hematology, December 9-11, 2011, San Diego, USA).
  39. Ellis J. Neufeld, Renzo Galanello, **Vip Viprakasit**, Yesim Aydinok, Antonio Piga, Paul Harmatz, Gian Luca Forni, Farrukh T Shah, Rachael F. Grace, John B. Porter, Elliott Vichinsky, John C Wood, Jennifer Peppe, Amber Jones and Hugh Y Rienhoff Jr. Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. (Presented as a poster presentation in the 53th Annual meeting of the American Society of Hematology, December 9-11, 2011, San Diego, USA).
  40. J Porter, M Cappellini, A Kattamis, **V Viprakasit**, T Lawniczek, J Ros, W Deng, A Taher. Relationships between plasma non-transferrin-bound iron and markers of iron overload, anemia and ineffective erythropoiesis in non-transfusion-dependent thalassaemia syndromes. (Presented as a poster presentation in the 16th European Haematology Association (EHA), June 9-12, 2011, London, UK).
  41. Nipon Chalaow, Suchada Riolueang, Chompunut Kanjanakorn, Kalaya Tachavanich, Chanin Limwongse, **Vip Viprakasit**. Validation of Multiplex Ligation-dependent Probe Amplification (MLPA) for rapid screening of Beta-globin gene cluster deletions in Thais. *Proceeding of the 12<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011. (Presented as a poster presentation).
  42. Nipon Chalaow, Suchada Riolueang, Kalaya Tachavanich, Vichai Laosombat, Marion Phylipsen, Cornelius L Harteveld, **Vip Viprakasit**. Identification of Two Novel beta globin cluster deletions causing Hereditary Persistent Fetal Haemoglobin (HPFH) in Thais: HPFH-Siriraj-1 and Siriraj-2. *Proceeding of the 12<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011. (Presented as an oral presentation).
  43. Suchada Riolueang, Supachai Ekwattanakit, Thongperm Munkongdee, Soavaros Svati, Pranee Winichagoon, Suthat Fucharoen, **Vip Viprakasit**. Predictive value of DNA methylation marks at -162 of the G and A-gamma globin promoters on determining clinical severity in Hb E/Beta Thalassemia. *Proceeding of the 12<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011. (Presented as an oral presentation).

44. Archwin Tanphaichitr, Thisarat Kusuwan, Siriporn Limviriyakul, Suvajana Atipas, Tuangrat Sangpraypan, Bunchoo Pongtanakul, Voravarn S Tanphaichitr, **Vip Viprakasit**. Incidence of ototoxicity in Thai thalassaemic patients after iron chelation therapy: comparison between desferrioxamine/combination therapy and new oral iron chelating agents. *Proceeding of the 12<sup>th</sup> International Conference on Thalassaemia and the Hemoglobinopathies*. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011. (Presented as a poster presentation).
45. Punyanuch Pornpanich, Suchada Riolueang, Waraporn Glomglao, Yaowapa Sukontharangsi, **Vip Viprakasit**. Neonatal screening for thalassaemia and haemoglobinopathies by isoelectric focusing (IEF) in Thai neonates. *Proceeding of the 12<sup>th</sup> International Conference on Thalassaemia and the Hemoglobinopathies*. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011. (Presented as a poster presentation).
46. Saiviroonporn P, **Viprakasit V**, Boonyasirinant T, Wood JC, and Krittayaphong R. Inter-Site Validation of the Pixel-Wise Method for Cardiac T2\* Analysis in 50 Transfusion-Dependent Thai Thalassaemia Patients. *Proceedings of ISMRM Nineteen Scientific Sessions*, Montreal, Canada, May 2011, (Traditional Poster).
47. Saiviroonporn P, **Viprakasit V**, Boonyasirinant T, Khuhapinant A, Wood JC, and Krittayaphong R. Comparison of the region-based and pixel-wise methods for cardiac T2\* analysis in 50 transfusion-dependent Thai Thalassaemia patients. *Proceedings of ISMRM Nineteen Scientific Sessions*, Montreal, Canada, May 2011, (Traditional Poster).
48. **Vip Viprakasit**, Norbert Gattermann, Jong Wook Lee, John B. Porter, Ali Taher, Dany Habr, Bernard Roubert, Gabor Domokos and Maria Domenica Cappellini. Geographical differences in transfusion and iron chelation practices in 1558 patients with transfusion-dependent anemias. (Presented as a poster presentation in the 52<sup>th</sup> Annual meeting of the American Society of Hematology, December 4-7, 2010, Orlando, USA).
49. Hugh Y. Rienhoff Jr., **Vip Viprakasit**, Lay H. Tay, Paul Harmatz, Janet Kwiatkowski, Amy E Tapper, John B Porter, and Ellis J. Neufeld. A Phase 1B dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of FBS0701, a novel oral iron chelator for the treatment of chronic iron overload. (Presented as a poster presentation in the 52<sup>th</sup> Annual meeting of the American Society of Hematology, December 4-7, 2010, Orlando, USA).
50. Dudley Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Continued Improvement and Normalization of Myocardial T2\* In Patients with  $\beta$  thalassaemia Major Treated with Deferasirox (Exjade®) for up to 3 Years. (Presented as a poster presentation in the 52<sup>th</sup> Annual meeting of the American Society of Hematology, December 4-7, 2010, Orlando, USA).
51. **Vip Viprakasit**, Karen Lower, Supachai Ekwattanakit, Suchada Riolueang, Voravarn S Tanphaichitr, Helena Ayyub, Chris Fisher, Bill Wood and Doug Higgs. Mutations in the EKLF gene lead to an unexpectedly severe phenotype in a family with thalassaemia.

*Proceeding and Abstract book for the 17<sup>th</sup> Haemoglobin Switching Meeting*. St. John College, Oxford, UK, 2-6 September 2010 (Presented as an oral presentation).

52. Martin Law, Karen M. Lower, Hsiao P. J. Voon, Jim R. Huges, David Garrick, **Vip Viprakasit**, Mathew Mitson, Marco De Gobbi, Yongjun Zhao, Andrew Morris, Aaron Abbott, Steven P. Wilder, Stephen Taylor, Guiherme M. Santos, Joe Cross, Helena Ayyub, Steven Jones, Jiannis Ragoussis, Daniela Rhodes, Ian Dunham, Douglas R. Higgs & Richard J. Gibbons. A SNF2 protein targets variable copy number repeats and thereby influences allele-specific expression. *Proceeding and Abstract book for the 17<sup>th</sup> Haemoglobin Switching Meeting*. St. John College, Oxford, UK, 2-6 September 2010 (Presented as an oral presentation).
53. Dudley J Pennell, John B Porter, M Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Deferasirox effectively removes cardiac iron in  $\beta$ -thalassemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy. *Proceeding and Abstract book for the 15<sup>th</sup> Congress of the European Hematology Association (EHA)*. Barcelona, Spain, 10-13 June 2010 (Presented as a publication only).
54. Dudley J Pennell, John B Porter, M Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Continued improvement in Cardiac T2\* with deferasirox treatment over 2 years: results from the extension of EPIC cardiac substudy in  $\beta$ -thalassaemia patients with myocardial siderosis. *Proceeding and Abstract book for the 15<sup>th</sup> Congress of the European Hematology Association (EHA)*. Barcelona, Spain, 10-13 June 2010 (Presented as a poster).
55. Ali Taher, **Vip Viprakasit**, John B Porter, Antonis Kattamis, Tomasz Lawniczek, Raffaele Pereno, Oliver Schoenborn-Kellenberger and M Domenica Cappellini. Factors associated with iron accumulation in non-transfusion-dependent thalassaemia syndromes: baseline data from multicenter international deferasirox study (THALASSA). *Proceeding and Abstract book for the 15<sup>th</sup> Congress of the European Hematology Association (EHA)*. Barcelona, Spain, 10-13 June 2010 (Presented as a publication only).
56. Dudley J Pennell, John B Porter, M Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Iron Chelation Therapy with Deferasirox (Exjade®) in Reducing Cardiac Siderosis in  $\beta$ -Thalassemia Patients: 2-Year Results from the EPIC Cardiac Substudy. *J. Am. Coll. Cardiol.* 2010; 55; A83.E785. (Presented as a poster presentation in the 59<sup>th</sup> Annual meeting of the American College of Cardiology, March 14-16, 2010, Atlanta, USA).
57. Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert and Ali Taher. Efficacy and safety of deferasirox (Exjade®) in  $\beta$ -Thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. *Blood*, 2009; 111(12): suppl.: 1863. (Presented as a poster presentation in the 51<sup>th</sup> Annual meeting of the American Society of Hematology, December 4-7, 2009, New Orleans, USA).

58. Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip **Viprakasit**, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, and Ali Taher. Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with  $\beta$ -Thalassemia. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 5106. (publication only)
59. Ali Taher, John B. Porter, Antonis Kattamis, Vip **Viprakasit**, Tomasz Lawniczek, Raffaele Pereno, Oliver Schoenborn-Kellenberger, and M. Domenica Cappellini. Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload. *Blood (ASH Annual Meeting Abstracts)*, Nov 2009; 114: 5111. (publication only)
60. Manop Pithukpakorn, Nuttakarn Yongsaraj, Suchada Riolueang, Nunthawut Chat-uthai, Chanin Limwongse, Vip **Viprakasit**. Further identification of C326Y mutation of the SCL40A1 underlying type-IV hereditary hemochromatosis in a Thai family. *Proceeding and Abstract book for the 1<sup>st</sup> Asia-Pacific Iron Academy (APIA)-Conference 2009: Iron in Health & Diseases*. The Shangri-La Hotel, Chiang Mai, Thailand, 26 – 29 November 2009 (Presented as an oral presentation).
61. Nuttakarn Yongsaraj, Suchada Riolueang, Nunthawut Chat-uthai and Vip **Viprakasit**. Molecular epidemiology of common TMPRSS6 variant (RS855791) associated with haemoglobin level and iron status in Thai population. *Proceeding and Abstract book for the 1<sup>st</sup> Asia-Pacific Iron Academy (APIA)-Conference 2009: Iron in Health & Diseases*. The Shangri-La Hotel, Chiang Mai, Thailand, 26 – 29 November 2009 (Presented as a poster presentation).
62. Vip **Viprakasit**, Pornpun Sripornsawan, Bunchoo Pongthanakul, Tuangrath Sangpraypan, Kalaya Tachavanich, and KleebSabai Sanpakit. Skin rash with mild –to-moderate severity is the most common adverse events associated with deferasirox: An evaluation for drug related adverse events in Thai paediatric patients with beta-thalassemia. *Proceeding and Abstract book for the 1<sup>st</sup> Asia-Pacific Iron Academy (APIA)-Conference 2009: Iron in Health & Diseases*. The Shangri-La Hotel, Chiang Mai, Thailand, 26 – 29 November 2009 (Presented as a poster presentation).
63. Thisarat Kusuwan, Tuangrath Sangpraypan, Vip **Viprakasit**. Cross-sectional analysis of patient's satisfaction to their chelation therapies comparing among: deferal, combined desferal+deferiprone (L1), monotherapy of deferiprone and deferasirox. *Proceeding and Abstract book for the 1<sup>st</sup> Asia-Pacific Iron Academy (APIA)-Conference 2009: Iron in Health & Diseases*. The Shangri-La Hotel, Chiang Mai, Thailand, 26 – 29 November 2009 (Presented as a poster presentation).
64. Vip **Viprakasit**, Worrawut Chinchang, Voravarn S. Tanphaichitr, Douglas R. Higgs. Heterogeneous spectrum of molecular basis of alpha-thalassemia in Thailand: a genotype analysis in 500 patients with Hb H disease. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).
65. Vip **Viprakasit**, Nunthawut Chat-Uthai, Waraporn Glomglaio, Lerlugh Suwanthon. Correlation between acute hemolytic crisis and Rbc properties in various types of thalassemias. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).

66. **Vip Viprakasit**, Pornpun Sripornsawan, Bunchoo Pongthanakul, Tuangrath Sangprayan, Kalaya Tachavanich. Evaluation of adverse events due to deferasirox: A novel oral iron chelator in 79 Thai pediatric patients with beta-thalassemia. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).
67. Jessada Buawbunnum, Kleebisabi Sanpakit, Bunchoo Pongthanakul, **Vip Viprakasit**. Growth impairment in patients with mild hemoglobin E/beta thalassemia. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).
68. **Vip Viprakasit**, Supachai Ekwattanakit, Yuwarat Monteerarat, Worrawut Chinchang, Kalaya Tachavanich. Association of *Xmn* I polymorphism and hemoglobin E haplotypes on post-natal gamma globin gene expression in homozygous hemoglobin E. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).
69. Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Amal El-Beshlawy, Lee Lee Chan, Yesim Aydinok, Mohsen Elalfy, Pranee Sutcharitchan, Chi-Kong Li, Hishamshah Ibrahim, **Vip Viprakasit**, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Abdel Hmissi and Ali Taher. Reduction and prevention of myocardial siderosis with deferasirox (Exjade®) in regularly transfused patients with  $\beta$ -thalassemia. *Proceeding and Abstract book for the 9<sup>th</sup> Cooley Anemia Symposium*. New York, USA, 21 – 24 October 2009 (Presented as a poster presentation).
70. Dudley Pennell, John B Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Li, **Vip Viprakasit**, Mohsen Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher. Efficacy and safety of deferasirox in reducing myocardial siderosis in patients with  $\beta$ -thalassemia major. *Proceeding and Abstract book for the 14<sup>th</sup> Congress of the European Hematology Association (EHA)*. Berlin, Germany, 4 – 7 June 2009 (Presented as a poster presentation).
71. A. Taher, A. Koren, H. Tamary, M.D. Cappellini, J.B. Porter, D. Habr, G. Domokos, B. Roubert and **V. Viprakasit**. Efficacy and safety of deferasirox in chelation-naïve patients with  $\beta$ -thalassaemia major: results from the large-scale EPIC Study. *Proceeding and Abstract book for the 14<sup>th</sup> Congress of the European Hematology Association (EHA)*. Berlin, Germany, 4 – 7 June 2009 (Presented as a poster presentation).
72. D.J. Pennell, J.B. Porter, M.D. Cappellini, A. El-Beshlawy, L.L. Chan, Y. Aydinok, M.S. Elalfy, P. Sutcharitchan, C.-K. Li, H. Shah, **V. Viprakasit**, A. Kattamis, G. Smith, D. Habr, G. Domokos, A. Hmissi, A. Taher. Efficacy and safety of deferasirox (Exjade®) in reducing and preventing myocardial siderosis in patients with  $\beta$ -thalassemia. *Proceeding and Abstract book for the Annual Bioiron Meeting*. Porto, Portugal, 7 – 11 June 2009 (Presented as a poster presentation).
73. **Vip Viprakasit**. Treatment with deferasirox (EXJADE®) in various anemias. *Proceeding and Abstract book for the 5<sup>th</sup> General Assembly Asian Hematology Association: Current Status and Problems of Global Clinical Trials: Progress in Hematology-2009*, Kobe Portopia Hotel, Kobe, Japan, February 13-14, 2009.
74. Supachai Ekwattanakit, Helena Ayyub, Kevin Clark, Fatima Marques-Kranc, Sue Butler, Jackie Sloane-Stanley, Jacqueline A Sharpe, Stefano Colella, Jiannis Ragoussis, **Vip Viprakasit**, Richard J Gibbons and Douglas R Higgs. Analysis of DNA Methylation

- at the Human Alpha Globin Cluster during Hematopoiesis. *Blood*, 2008; 111(12): suppl.: 1861. (Presented as a poster presentation in the 50<sup>th</sup> Annual meeting of the American Society of Hematology, San Francisco, CA, USA).
75. Supachai Ekwattanakit, Suchada Riolueang and **Vip Viprakasit** Epigenetic Analysis of Beta-Globin Gene Cluster during Hematopoiesis. *Blood*, 2008; 111(12): suppl.: 1863. (Presented as a poster presentation in the 50<sup>th</sup> Annual meeting of the American Society of Hematology, San Francisco, CA, USA).
76. Maria Domenica Cappellini, Norbert Gattermann, **Vip Viprakasit**, Jong Wook Lee, John B Porter, Amal El-Beshlawy, Antonis Kattamis, John F Seymour, Chi-Kong Li, Dany Habr, Gabor Domokos, Abdel Hmissi and Mohsen Saleh Elalfy. Transfusion History, Iron Chelation Practices and Status of Iron Overload across Various Transfusion-Dependent Anemias: Data from the Large-Scale, Prospective, 1-Year EPIC Trial. *Blood*, 2008; 111(12): suppl.: 1863. (Presented as a poster presentation in the 50<sup>th</sup> Annual meeting of the American Society of Hematology, San Francisco, CA, USA).
77. Warankana Thongnoppakun & **Vip Viprakasit**. Molecular epidemiology of Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) mutations in Thailand. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 73 p 37 (Presented as an oral presentation).
78. Monteerarat Yuwarat, Glomglao Waraporn, **Vip Viprakasit** Molecular epidemiology of five common Thipurine-s-Methyl Transferase (TPMT) variants in Thailand. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 52 p 26 (Presented as an oral presentation).
79. Pornpun Sripornsawan, Bunchoo Pongtanakul, **Vip Viprakasit**. Prospective clinical evaluation for serious adverse events and complications due to deferiprone (L-1) in Thai pediatric patients. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 66 p 33 (Presented as an oral presentation).
80. Pornpun Sripornsawan, Bunchoo Pongtanakul, Noppadol Siritanaratkul, **Vip Viprakasit**. Expected and unexpected adverse events due to deferasirox; a novel oral iron chelator in 79 Thai patients with transfusional iron overload. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 68 p 34 (Presented as an oral presentation).
81. Pornpun Sripornsawan & **Vip Viprakasit**. Increase severity of hemolytic crisis in G-6-PD deficiency due to coinheritance of thalassemia syndromes: a preliminary report from Siriraj Hospital. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 153 p52 (Presented as a poster presentation).

82. Warankana Thongnoppakun, Krongjit Lekpetch, **Vip Viprakasit**. Homozygotes and compound heterozygotes of UGT1A1 gene mutations causing Gilbert syndrome in Thailand. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 113 p57 (Presented as a poster presentation).
83. Warankana Thongnoppakun, Nuntana Siripipattanamongkol, Ajima Treesucon, Voravarn S Tanphaichitr, **Vip Viprakasit**. Molecular spectrum of Glucose-6-Phosphate Dehydrogenase variants in pediatric patients with acute hemolytic crisis and neonatal jaundice. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 114 p57 (Presented as a poster presentation).
84. Prapa Aroonyadet, Kalaya Tachavanich, Voravarn S. Tanphaichitr, **Vip Viprakasit**. Clinical manifestation and natural history of red cell membrane disorders in Thai pediatric patients. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 115 p58 (Presented as a poster presentation).
85. Kalaya Tachavanich, **Vip Viprakasit**, Gavivann Veerakul, Kochpinchorn Chansing, Voravarn S Tanphaichitr. Development of a comprehensive red blood cell enzymopathy laboratory in Thailand. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 117 p59 (Presented as a poster presentation).
86. Suwannee Phumeetham, Nunthawut Chat-uthai, Manutham Manavathongchai, **Vip Viprakasit**. Genetic susceptibility to sepsis in Thailand: a preliminary report from Thailand Pediatric Sepsis-Study Group. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 128 p64 (Presented as a poster presentation).
87. Nunthawut Chat-uthai, Suwannee Phumeetham, **Vip Viprakasit**. Molecular epidemiology and haplotype structures of Tumor Necrosis Factor-Alpha (TNF- $\alpha$ ) promotor polymorphisms in Thai Population. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 130 p65 (Presented as a poster presentation).
88. Tawatchai Suwanban & **Vip Viprakasit**. Compound heterozygotes for Hemoglobin Paksé and Pak Num Po: A novel thalassemia intermedia syndrome. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 166 p83 (Presented as a poster presentation).
89. Suchada Riolueang & **Vip Viprakasit**. Identification of rare translation initiation codon (ATG) mutation causing Hemoglobin H disease. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 167 p84 (Presented as a poster presentation).



90. Jessada Buawbunnum & **Vip Viprakasit** Longitudinal analysis of growth and height development in Hemoglobin E/Beta Thalassemia who rarely required blood transfusion. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 168 p84 (Presented as a poster presentation).
91. Bunchoo Pongtanakul, Prapun Aanpreung, **Vip Viprakasit**. Incidence and the Effect of helicobacter pylori infection in Thai children with chronic thrombocytopenic purpura. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 184 p92 (Presented as a poster presentation).
92. Yuwarat Monteerarat, Prasert Auewarakul, **Vip Viprakasit**. Identification of the main human receptor for avain influenza (H5N1) infection using *in vitro* knock down RNA interference. *Journal of Hematology and Transfusion Medicine: Abstract book for the XXXII<sup>nd</sup> World Congress of The International Society of Hematology*. Bangkok, Thailand, 19-23 October 2008; 18 (suppl.): abs 220 p110 (Presented as a poster presentation).
93. Nunthawut Chat-Uthai & **Vip Viprakasit**. Different osmotic containment in various types of thalassemias correlated with clinical hemolysis. *Proceeding of the 11<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Suntec International Convention, Singapore, 8-11 October 2008. (Presented as an oral presentation and this work was granted “Novartis Travel Award 2008”).
94. Suchada Riolueang , Supachai Ekwattanakit, **Vip Viprakasit**. Significant epigenetic marks identified through methylation profile analysis of the G-gamma and A-gamma globin genes using MALDI-TOF Mass Spectrometry and methylation cloning. *Proceeding of the 11<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Suntec International Convention, Singapore, 8-11 October 2008. (Presented as a poster presentation and this work was granted “Novartis Travel Award 2008”).
95. Pornpun Sripornsawan, Kalaya Tachavanich, **Vip Viprakasit**. Clinical evaluation on adverse events due to deferasirox; a novel oral iron chelator, in 79 pediatric patients with  $\beta$ -thalassemia. *Proceeding of the 11<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Suntec International Convention, Singapore, 8-11 October 2008. (Presented as a poster presentation and this work was granted “Novartis Travel Award 2008”).
96. Thisarat Kusuwan, Tuangrath Sangpraypan & **Vip Viprakasit**. Cross-Sectional Analysis of Patient's Satisfaction to Their Chelation Therapies Comparing Among; Desferal, combined Desferal + Deferiprone (L1), monotherapy of Deferiprone and Deferasirox. *Proceeding of the 11<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Suntec International Convention, Singapore, 8-11 October 2008. (Presented as a poster presentation).
97. Bunchoo Pongtanakul, Prapan Aanpreung, **Vip Viprakasit**. Incidence and the Effect of Helicobacter Pylori Infection in Thai Children with Chronic Thrombocytopenic Purpura. *Proceeding of the 5<sup>th</sup> Asian-Pacific Congress on Thrombosis and Hemostasis*. Grand

- Copthorne Waterfront, Singapore, 17-19 September 2008. (Presented as a poster presentation).
98. **Vip Viprakasit**, Pharmacogenomics in childhood malignancy. Symposium session on Pharmacogenomics in Clinical Genetics. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; SS5-3. (invited speaker).
  99. Waraporn Glomglao, Worrawut Chinchang & **Vip Viprakasit**. Validation analysis of the newly developed single tube multiplex  $\beta$ -thalassemia arms-PCR in routine laboratory setting. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; P-85. (Poster presentation).
  100. Warankana Thongnoppakun & **Vip Viprakasit**. A preliminary analysis of *UGT1A1* gene polymorphisms on bilirubin metabolism in beta thalassemia patients in Thailand. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; P-88. (Poster presentation).
  101. **Vip Viprakasit** & Kalaya Tachavanich. A comparative analysis between “Mahidol HB E/thal” and “thalassemia international federation (TIF)” scoring criteria for clinical severity grading in haemoglobin E/ $\beta$  thalassemia. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; SS5-3. (Poster presentation).
  102. Nunthawut Chat-Uthai, Issra Songmahachai, Yonrawee Piyakom, Wiyakarn Utto, Lerluk Suwanthol & **Vip Viprakasit**. *IN VITRO* study of red blood cells osmotic fragility and acidic resistance in different thalassemia syndromes suggests role of red blood cell pathobiology underlying acute haemolytic crisis. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; P-114 (Poster presentation).
  103. Punyanuch Pornpanich, Waraporn Glomglao & **Vip Viprakasit**. Comparative analysis on laboratory diagnosis of thalassemia and haemoglobin disorders between liquid chromatography and ISO-electric focusing in 2,077 thais. *Program and abstracts book for the Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; P-101 (Poster presentation).
  104. Suchada Riolueang, Worrawut Chinchang & **Vip Viprakasit**. First identification of HB westmead (alpha 122 (H5) HIS-GLN) in two unrelated thai families and its interaction with beta thalassemia/Hemoglobin E. *Program and abstracts book for the*

- Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics*. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008; P-82. (Poster presentation).
105. **Vip Viprakasit**, Pairunyar Sawathiparnich, Tuanrat Sangpraypan, Linda Weerakulwattana, Pornpimol Kiattisakthavee, Katharee Chaichanwatanakul & Natsawee Watana. Osteopenia is commonly present in prepubertal children with severe Hb E/ $\beta$ -thal despite adequate transfusion and iron chelation therapy. *Blood*, 2007; 110(11): suppl.: 26b.
106. **Vip Viprakasit**. Update on Molecular Genetics of Thalassemia. *Program and abstracts book for the Joint Symposia; Medical Genetics Update 2007 7 Second Genetic Metabolic Symposium*. Bangkok, Thailand, November 6-7, 2007 (invited speaker).
107. **Vip Viprakasit**. Genetic abnormalities in G6PD; Symposium IX on G6PD Deficiency. *Program and abstracts book for the 6<sup>th</sup> Asia Pacific Regional Meeting of the International Society of Neonatal Screening*. Furama Hotel, Singapore, August 29 - September 1, 2007. (invited speaker)
108. **Vip Viprakasit**. Thalassemia intermedia-pathophysiology and complications. *Program and abstracts book for Asia Pacific Summit-New Horizon in Treating Hematological Diseases-translating science, building alliance*. Jeju Island, South Korea, July 6-9, 2007 (invited speaker)
109. Pairunyar Sawathiparnich, Linda Weerakulwattana, Pornpimol Kiattisakthavee, Katharee Chaichanwatanakul & **Vip Viprakasit**. Osteopenia is commonly present in prepubertal children with severe  $\beta$ -thal/Hb E despite adequate transfusion therapy. *Hormone Research*, 2007; 68: suppl.1, 64. (Presented as a poster presentation in the 46<sup>th</sup> Annual Meeting of the European Society for Paediatric Endocrinology (ESPE), Helsinki, Finland, June 27-30, 2007).
110. **Vip Viprakasit**. Gene therapy in thalassemia. *Program and abstract book for 4<sup>th</sup> Annual Meeting of Asian Hematology Association (AHA)*. Bangkok, Thailand, February 24- 25, 2007 (invited speaker).
111. **Vip Viprakasit**, Yuwarat. Monteerarat, Orathai Piboonpocanun, Kleesabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond. Identification of a novel IL7RA mutation (444\_450 insA) caused marked reduction in CD127 expression from a cohort molecular analysis of severe combined immunodeficiency (T<sup>-</sup>, B<sup>+</sup>, NK<sup>+</sup> SCID) in Thailand. *Blood*, 2006; 107(11): suppl.: 523a. (Presented as a poster presentation in the 48<sup>th</sup> Annual meeting of the American Society of Hematology, Orlando, Florida).
112. Yuwarat. Monteerarat, Orathai Piboonpocanun, Kleesabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond, **Vip Viprakasit**. Characterization of a novel *IL7RA* mutation (444\_450 insA) caused marked reduction in CD 127 expression highlighting an important role of interleukin-7 receptor  $\alpha$  on T-cell development. *Program and abstract book for 8th*

*International Meeting on Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases*. Bangkok, Thailand, November 30- December 2, 2006 (Presented as an oral presentation).

113. D.R. Higgs, D. Garrick, E. Anguita, J. Hughes, **V. Viprakasit**, A. Argentaro, D. Vernimmen, R.J. Gibbons & W.G. Wood. The Regulation of the Human  $\alpha$  Globin Gene Cluster. *Program and abstract book for European School of Genetic Medicine 3<sup>rd</sup> Course in Thalassemia*. Bertinoro di Romagna, Italy, June 24<sup>th</sup> - 28<sup>th</sup>, 2006
114. Helene Puehringer, Hossein Najmabadi, Hai-Yang Law, Walter Krugluger, **Vip Viprakasit**, Serge Pissard, Ali Taher, Ameen K. Al-Ali, Christian Oberkanins. Analysis of common alpha-thalassemia point mutations and deletions by reverse-hybridization. *Program and abstract book for 11<sup>th</sup> International Congress of Human Genetics*, Brisbane, Australia, August 6-10, 2006 (Presented as a poster presentation).
115. Yuwarat. Monteerarat, Orathai Piboonpocanun, Kleesabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond, **Vip Viprakasit**. Molecular analysis of severe combined immunodeficiency in Thailand. *Program and abstract book for 11th International Congress of Human Genetics*, Brisbane, Australia, August 6-10, 2006 (Presented as a poster presentation).
116. **Vip Viprakasit**. Problems in determining thalassaemia carrier status in a program for prevention and control of severe thalassemia syndromes. *Proceeding of the 10<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Dubai, United States of Arab Emirate, 7-10 January 2006. (Presented as a poster presentation).
117. **Vip Viprakasit**. HS-33 is not sufficient to rescue the  $\alpha$  globin gene expression in a novel upstream deletion involved the  $\alpha$  MRE/HS-40. *Proceeding of the 10<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Dubai, United States of Arab Emirate, 7-10 January 2006. (Presented as an oral presentation).
118. Marco De Gobbi, **Vip Viprakasit**, Pieter J. de Jong, Yuko Yoshinaga, Jan-Fang Cheng, Jim R. Hughes, Chris A. Fisher, William G. Wood, Donald K. Bowden, Douglas R. Higgs. Identification of a Gain-of-Function SNP Causing a New Model of  $\alpha$ -Thalassaemia. *Blood*, 2005; 106(11): suppl.: 523a. (Presented as an oral presentation in the 47<sup>th</sup> Annual meeting of the American Society of Hematology, Atlanta, Georgia).
119. **Vip Viprakasit**, Marco De Gobbi, Helena Ayyub, Ioannis Ragoussis, William G. Wood, Donald K. Bowden, Douglas R. Higgs. An Entirely Novel Form of  $\alpha$ -Thalassemia in Patients from the South Pacific Linked to Chromosome 16. *Blood*, 2005; 106(11): suppl.: 2688a. (Presented as a poster presentation in the 47<sup>th</sup> Annual meeting of the American Society of Hematology, Atlanta, Georgia).
120. Sookkasem Khositseth, **Vip Viprakasit**, Nunghathai Swasedee, Worrawut Chingchang, Achara Paemane, Sirintra Nakjang, Duangrurdee Wattanasirichaigoon, Pa-Thai Yenchitsomanus. Digenic inheritance of Anion Exchanger 1 (SIC4A1) and Human Globin (HBA, HBB) mutations results in Distal Renal Tubular Acidosis and chronic

- hemolytic anemia in Thai patients. *Proceeding of the 9<sup>th</sup> Asian Congress of Pediatric Nephrology*. Beijing, China. October 28-30, 2005. (Presented as an oral presentation).
121. Anirut Pattaragarn, Achra Sumboonnanonda, **Vip Viprakasit**, Suroj Supavekin, Vibul Suntornpoch. Immune-mediated hemolytic anemia in pediatric renal transplantation. *Proceeding of the 9<sup>th</sup> Asian Congress of Pediatric Nephrology*. Beijing, China. October 28-30, 2005. (Presented as a poster presentation).
122. S. Colella, L. Marcelline, **V. Viprakasit**, S. Smile, R.J. Gibbons, D. R. Higgs and J. Ragoussis. MassCleave and MassExtend assays to detect and quantify CpG sites methylation levels in the genome. *Proceeding of the ESF Functional Genomics Conference*, Oslo, Norway. September 06-09, 2005. (Presented as an oral presentation).
123. Ragoussis, J., Marcelline, L., **Viprakasit, V.**, Smile, S., Gibbons, R.J., Higgs, D.R., Colella, S. High-throughput detection and quantification of CpG sites methylation levels in the genome using MASSCleave technology. *Proceeding of the American Society of Human Genetics*, Salt Lake City, UT, USA. October 25-29, 2005. (Presented as an oral presentation).
124. Helene Puehringer, Hossein Najmabadi, Hai-Yang Law, Walter Krugluger, **Vip Viprakasit**, Serge Pissard, Ali Taher, Ameen K. Al-Ali, Christian Oberkanins. Analysis of common alpha thalassemia point mutations and deletions by reverse hybridization. *Proceeding of the 10<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Dubai, United States of Arab Emirate, 7-10 January 2006. (Presented as a poster presentation).
125. H. Drakesmith, L. Schimanski, A. Omerode, A. Merryweather-Clarke, **V. Viprakasit**, Yingyong Chinthammitr, Emma Sweetland, Judy Bastin, Diana Cowley, Jon Edwards, Kathryn Robson and Alain Townsend. Ferroportin mutations have two different effects on protein function; loss of export capacity or resistance to inhibition by hecidin *Proceeding of the BIOIRON Congress 2005*, Prague, Czech Republics, May 23-27, 2005). (Presented as an oral presentation).
126. H. Puehringer, H. Najmabadi, E. Baysal, W. Krugluger, H.Y. Law, **V. Viprakasit**, C. Oberkanins. Comprehensive alpha- and beta-thalassemia genotyping by means of reverse-hybridization teststrips. *Proceeding of 10<sup>th</sup> Congress of the European Haematology Association*, Stockholm, Sweden, June 2-5, 2005 (Presented as a poster presentation).
127. Gernot Kriegshaeuser, Hossein Najmabadi, Erol Baysal, Walter Krugluger, Hai Yang Law, **Vip Viprakasit**, Helene Puehringer and Christian Oberkanins. Comprehensive Alpha- and Beta-Thalassemia Genotyping by Means of Reverse-Hybridization Teststrips. *Proceeding of the HUGO's 10<sup>th</sup> Human Genome Meeting*, Kyoto, Japan, April 18- 21, 2005 (Presented as a poster presentation).
128. **Vip Viprakasit**, Alison T. Merryweather-Clarke, Yingyong Chinthammitr, Lisa Schimanski, Somdet Srichairatanakool, Chanin Limwongs, Alain Townsend and Kathryn J. H. Robson. Molecular diagnosis of the first ferroportin mutation (C326Y) in the Far East causing a dominant form of inherited iron overload. *Blood*, 2004; 102(11): suppl.: 2799a.

(Presented as a poster presentation in the 46<sup>th</sup> Annual meeting of the American Society of Hematology, San Diego, California).

129. O. Trachoo, T. Sura, D. Dejsuphon, S. Theerasasawat, A. Tunteeratum, M. Busabaratana, **V. Viprakasit**, S. Sritara. Genomic screening of non-deletional  $\alpha$  thalassemia in Thai population. Conference Program & Presentation Abstract: P-155, Biopolis, Singapore, November 17-20, 2004 (Presented as a poster).
130. **Vip Viprakasit**, Yingyong Chinthamitr, Worawut Chinchang and Theera Ruchutrakool. Identification of Antithrombin-Siriraj, a novel signal peptide mutation cause type-I antithrombin deficiency in Thai patients. *Proceeding of the Third Asian-Pacific Congress on Thrombosis and Hemostasis*: O-4, Bangkok, Thailand, October 14- 16, 2004 (Presented as an oral presentation).
131. P. Charoenkwan, S. Likasitwattanakul, **V. Viprakasit**, V. S. Tanphaichitr, P. Thanarattanakorn, T. Sanguansermisri. Secondary prevention for thrombotic complication in homozygous hemoglobin Tak. *Proceeding of the Third Asian-Pacific Congress on Thrombosis and Hemostasis*: P-52, Bangkok, Thailand, October 14- 16, 2004 (Presented as a poster presentation).
132. V. Laosombat, B. Sattayasevana, **V. Viprakasit**, T. Shirakawa, M. Matsuo. A new glucose-6-phosphate dehydrogenase variant, G6PD Songklanagarind 196 (T $\rightarrow$ A), in the Thai population. *Proceeding of the 12<sup>th</sup> ASEAN-Pediatrics Federation Conference; "Impact of Child Care on Adult Diseases"*: FP-E1, Dusit Resort, Pataya, Thailand, November 26-28, 2004 (Presented as a poster presentation).
133. Lisa Schimanski, Hal Drakesmith, Alison Merryweather-Clarke, **Vip Viprakasit**, Yingyong Chinthamitr, Emma Sweetland, Judy Bastin, Diana Cowley, Jon Edwards, Kathryn Robson and Alain Townsend. Functional studies on human ferroportin and naturally occurring mutations of the gene, implicated in type IV haemochromatosis. *Proceeding of the Annual Meeting of The European Iron Club* (Presented as an oral presentation in the Annual Meeting of The European Iron Club, Rennes, France, September 8-11, 2004).
134. **Vip Viprakasit**, Voravarn S. Tanphaichitr, Worawut Chinchang, Mitch J. Weiss and Douglas R. Higgs. Genetic Study and Haplotype Analysis of Alpha Hemoglobin Stabilizing Protein (AHSP) in  $\beta$  thalassaemia/Hb E Disease with Variable Clinical Severity. *Blood*, 2003; 102(11): suppl.: 953a. (Presented as a poster presentation in the 45<sup>th</sup> Annual meeting of the American Society of Hematology, San Diego, California).
135. Alison T. Merryweather-Clarke, Estelle Cadet, Adrian Bomford, Dominique Capron, **Vip Viprakasit**, Anne Miller, PJ McHugh, Jane Collier, Roger Chapman, Jennifer J Pointon, Victoria LC Wimhurst, Voravarn Tanphaichitr, Jacques Rochette & Kathryn JH Robson. Digenic inheritance of mutations in *HAMP* and *HFE* result in different types of haemochromatosis. *Blood*, 2003; 102(11): suppl.: 2799a. (Presented as a poster presentation in the 45<sup>th</sup> Annual meeting of the American Society of Hematology, San Diego, California).

136. **Vip Viprakasit\*** & Voravarn S. Tanphaichitr. An unusual phenotype of Hb EE with Hb H disease: a pitfall in clinical diagnosis and genetic counseling. *Blood*, 2003; 102(11): suppl.: 3846a.
137. **Vip Viprakasit**, Voravarn S. Tanphaichitr, Worrawut Chinchang, Mitch J. Weiss and Douglas R. Higgs. Genetic Study and Haplotype Analysis of Alpha Hemoglobin Stabilizing Protein (AHSP) in  $\beta$  thalassaemia/Hb E Disease with Variable Clinical Severity. *Proceeding of the 9<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Palermo, Italy, 16-19 October 2003. (Presented as an oral presentation).
138. **Vip Viprakasit**, Prin Vathesathokit, Worrawut Chinchang, Kalaya Tachavanich, Parichat Pung-Amritt, Pathai Yenchitsomanus, Alison T. Merryweather-Clarke and Voravarn S. Tanphaichitr. Prevalence of *HFE* mutations among Thai population and its correlation with iron overload in hemoglobin E disorder. *Proceeding of the 9<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Palermo, Italy, 16-19 October 2003. (Presented as an oral presentation).
139. D. R. Higgs, D. Garrick, E. Anguita, J. Hughes, **V. Viprakasit**, A. Argentaro, R.J. Gibbons, W.G. Wood. The regulation of  $\alpha$  globin gene expression. *Proceeding of the 9<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies*. Palermo, Italy, 16-19 October 2003.
140. Eduardo Anguita, Jim Hughes, **Vip Viprakasit**, Jacqueline Sharpe, Jacqueline A. Sloane-Stanley, Cristina Tufarelli, William G. Wood and Douglas R. Higgs. Deletion of the mouse  $\alpha$  globin regulatory element (HS-26) has an unexpected mild phenotype. *Proceeding of the Thirteenth Conference on Hemoglobin Switching*. Oxford, UK, 26-30 September 2002.
141. **Vip Viprakasit**, Richard J. Gibbons, Bernard C. Broughton, Alan R. Lehmann & Douglas R. Higgs. Mutations in a general transcription factor, TFIID result in a novel unlinked form of  $\beta$ -thalassaemia in individuals with Trichothiodystrophy. *Blood*, 2001; 98 (11) suppl.: 438a. (Presented as an oral presentation in the 43<sup>rd</sup> Annual Meeting of American Society of Haematology, Orlando, Florida, 7-11 December 2001).
142. **Vip Viprakasit**, Richard J. Gibbons, Bernard C. Broughton, John L. Tolmie, Donald Brown, Peter Lunt, Robin M. Winter, Stefano Marinoni, Miria Stefanini, Louise Brueton, Alan R. Lehmann & Douglas R. Higgs. Unlinked form of  $\beta$ -thalassaemia caused by mutations in XPD gene on chromosome 19q13.2. *The Hematology Journal*, 2001; 1 suppl.: 87. (Presented as an oral presentation in the 6<sup>th</sup> European Haematology Association Meeting (EHA), Frankfurt, Germany, June 21-24, 2001).
143. **Viprakasit V**, Pung-Amritt P, Petrarat S, Veerakul G, Higgs DR and Tanphaichitr VS. A novel  $\alpha$ -1 gene mutation causes severe  $\alpha$  thalassaemia phenotype (Hb Pak Num Po). *Proceeding of the 8<sup>th</sup> International Conference on Thalassemia and the Hemoglobinnopathies*. The Panhellenic Thalassemia patient association, Athens, 2001: 131-2. (Presented as an oral presentation in the 8<sup>th</sup> International Conference on Thalassaemia, Athens, Greece, October 18-21, 2001).
144. **Vip Viprakasit**, Richard J. Gibbons, John L. Tolmie, Peter Lunt, Robin M. Winter, Bernard C. Broughton, Alan R. Lehmann & Douglas R. Higgs. Identification of Mutations in a Trans-Acting Factor with different effects on  $\alpha$  and  $\beta$  globin expression. *Blood Cells, Molecules, and Diseases*, 2000; 26(5): 497. (Presented as a poster at the 12<sup>th</sup> Conference on Haemoglobin Switching, Seattle, USA, June 9-13, 2000).

145. **Viprakasit V**, Tanphaichitr VS, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P and Suvatte V. Linear Growth in Thalassemic Patients Under Different Transfusion Regimen. *Proceeding of the 7th International Conference on Thalassemia and the Hemoglobinnopathies. Ministry of Public Health, Thailand, 1999* Bangkok: 269. (Presented as an oral presentation in the 7<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies, Bangkok, Thailand, 31 May-4 June 1999).



## PROCEEDINGS OF NATIONAL MEETINGS AND CONFERENCES

1. Nipon Chalaow, Marion Phylipsen, Suchada Riolueang, Nunthawut Chat-Uthai, Corneilis Hartevelde, **Vip Viprakasit**. Molecular Characterization of SEA-type deletion of the Beta-globin Gene Cluster using Combined Multiplex Ligation dependent Probe Amplification (MLPA) and Array Comparative Genomic Hybridization (a-CGH). The national and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, Faculty of Medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012.(oral presentation)
2. Porntep Tanyut, Pornpimol Ruengwuttillert, Tuangsit Wataganara, Suchada Riolueang, Nunthawut Chat-Uthai, Waraporn Glomglao, Chompunut Kanjanakorn, Chnin Limwongse, **Vip Viprakasit**. A New Prenatal Diagnostic Strategy for Detection of Hb Bart's Hydrops' Fetalis Using Chorionic Villous DNAs in Early Pregnancy. National and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, faculty of medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012.(poster presentation)
3. Sirirat Wijit, Bunchoo Pongtanakul, Kleebasabi Sanpakit, Suchada Riolueang, Nipon Chalaow, Wiyakan Utto, Nuntawut Chat-Uthai, **Vip Viprakasit**. Severe Hyperbilirubinemia with Transaminitis in a Patient with Hb H-CS due to Coinheritance of Gilbert's Syndrome: The First Case Report in Thailand. The national and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, Faculty of Medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012.(poster presentation)
4. Narawadee Rujanapun, Duangkamol Phummiratch, Sasitorn Aueviriyavit, Suchada Riolueang, Nipon Chalaow, Rawiwan Maniratanachote, **Vip Viprakasit**. *In vitro* toxicological effects of silver nanoparticles in human hematological cell lines. The national and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, Faculty of Medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012. (poster presentation)
5. Nipon Chalaow, Marion Phylipsen, Suchada Riolueang, Kalaya Tachavanich, Vichai Laosombat, Cornelius L. Hartevelde, **Vip Viprakasit**. Molecular Characterization of A Novel Beta Globin Gene Cluster Deletions in Thais: Siriraj-thalassemia ( $\gamma$  ( $^A\gamma\delta\beta$ )<sup>o</sup>) using MLPA and CGH Technology. The national and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, Faculty of Medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012.(poster presentation)
6. Suchada Riolueang, Waraporn Glomglao, Kalaya Techawanich, Kotpichon Chansing, Nipon Chalaow, Supachai Ekwattanakit, **Vip Viprakasit**. The Origin of Sickle Cell Disease (SCD) in Thailand. The national and international conference in medicine and public health to commemorate the 150<sup>th</sup> anniversary of birth of Queen Sri Savarindira, Faculty of Medicine Siriraj hospital, Mahidol university, Thailand;17-21 september 2012.(poster presentation)
7. Suchada Riolueang, Waraporn Glomglao, Varangkana Navichit, Nipon Chalaow, Nuttakarn Yongsaroj, Rapeepun Shompoopueng, Nunthawut Chat-Uthai & **Vip Viprakasit** Molecular Identification of a rare  $\alpha^+$ -thalassemia (IVS I-I: G-A) with a common SEA deletion resulting in a very mild Hb H disease in a Thai boy. *Program and*

*abstract book for 17<sup>th</sup> National Thalassemia Conference*, Rama Garden Hotel, Bangkok, Thailand. September 7-9, 2011 (Poster presentation).

8. Suchada Riolueang, Nunthawut Chat-Uthai, Waraporn Glomglao, Varangkana Navichit, Chompunut Kanjanakorn, Chnin Limwongse & **Vip Viprakasit** Successful Prenatal Diagnosis for Hb Bart's Hydrops' Fetalis Using Chorionic Villous DNAs in Early Pregnancy. *Program and abstract book for 17<sup>th</sup> National Thalassemia Conference*, Rama Garden Hotel, Bangkok, Thailand. September 7-9, 2011 (Poster presentation).
9. Wilaslak Tanongsaksakul, Nipon Chalaow, Suchada Riolueang, Varangkana Navichit, Nuttakarn Yongsaroj, Rapeepun Shompoopong, Nunthawut Chat-Uthai & **Vip Viprakasit**. First Molecular Characterization of Hb A2-Melbourne (GAG-AAG) Through Thalassemia and Hemoglobinopathy Screening Program in Thai Teenage Students. *Program and abstract book for 17<sup>th</sup> National Thalassemia Conference*, Rama Garden Hotel, Bangkok, Thailand. September 7-9, 2011 (Oral presentation).
10. Nuttakarn Yongsaroj, Nunthawut Chat-Uthai, Suchada Riolueang, Nipon Chalaow, Rapeepun Shompoopong, Varangkana Navichit & **Vip Viprakasit**. Molecular Diagnosis of Common Promoter Polymorphism of the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Using a Real-time PCR with High Resolution Melting (HRM) Analysis. *Program and abstract book for 17<sup>th</sup> National Thalassemia Conference*, Rama Garden Hotel, Bangkok, Thailand. September 7-9, 2011 (Poster presentation).
11. Sasitorn Aueviriyavit, Duangkamol Phummiratch, Suchada Riolueang, Nipon Chalaow, **Vip Viprakasit** and Rawiwan Maniratanachote. In Vitro Effects of Silver Nanoparticles (AgNPs) Upon Apoptosis and Cytotoxicity in Human Lymphoblastoid and Primary Erythroid Cells. *Program and abstract book for the 39<sup>th</sup> Annual Meeting of The Thai Society of Hematology: Advances in Hematology*, Centara Grand Hotel, Bangkok, Thailand, March 7-10, 2011 (oral presentation)
12. Nunthawut Chat-Uthai, Suchada Riolueang, Rapeepun Shompoopong, Waraporn Glomglao, Chompunut Kanjanakorn, Chanin Limwongse & **Vip Viprakasit**. Technical Improvement for Hb Bart's Hydrops' Diagnosis in Chorionic Villous Samples Using A Highly Sensitive qPCR and Melting-Peak Analysis for Detecting South East Asian Type of  $\alpha$  globin Deletion (--SEA). *Program and abstract book for 16<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. September 12-14, 2010 (Oral presentation).
13. Suchada Riolueang, Nunthawut Chat-Uthai, Waraporn Glomglao, Chompunut Kanjanakorn, Chanin Limwongse & **Vip Viprakasit**. Definitive diagnosis for beta-globin mutations using a real-time PCR with high resolution melting (HRM) analysis: not just only mutation screening. *Program and abstract book for 16<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. September 12-14, 2010 (Oral presentation).

14. Nipon Chalaow, Suchada Riolueang, Chompunut Kanjanakorn, Kalaya Tachavanich, Chanin Limwongse & **Vip Viprakasit**. Validation of multiplex ligation-dependent probe amplification (MLPA) for rapid screening of beta-globin gene cluster deletions in Thais. *Program and abstract book for 16<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. September 12-14, 2010 (Oral presentation).
15. Pairash Saiviroonporn, **Vip Viprakasit**, Thananya Boonyasirinant, Archrob Khuhapinant, John C. Wood & Rungroj Krittayaphong. Comparison of the region-based and pixel-wise methods for cardiac T2\* analysis in 50 transfusion-dependent Thai thalassemia patients. *Program and abstract book for 16<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. September 12-14, 2010 (Oral presentation).
16. Suchada Riolueang, Supachai Ekwattanakit, Thongperm Munkongdee, Suthat Fucharoen, Pranee Winichagoon & **Vip Viprakasit**. Detection of Different Methylation Levels Using Combined Bisulphite Restriction Analysis (COBRA) of the G- and A-Gamma Globin Promoters in Primary Erythroid Cell Culture from Patients with Hb E/Beta Thalassemia. *Program and abstract book for 15<sup>th</sup> National Thalassemia Conference*, Charoensri Grand Hotel, Khon Khen, Thailand. April 22-24, 2009 (Poster presentation).
17. Punyanuch Pornpanich, Waraporn Glomglao, Suchada Riolueang, Supachai Ekwattanakit, Kitti Torcharut & **Vip Viprakasit**. Laboratory Diagnosis of Hb E with or without Alpha Thalassemia at Birth Using Iso-Electric Focusing (IEF) and Iso-Scanning Method. *Program and abstract book for 15<sup>th</sup> National Thalassemia Conference*, Charoensri Grand Hotel, Khon Khen, Thailand. April 22-24, 2009 (Poster presentation).
18. Waraporn Glomglao, Kochpinchon Chansing, Kalaya Tachavanich & **Vip Viprakasit**. Hematological Parameters in Individuals who Inherited Two Defective Alpha-Thalassemia Genes *in cis* or *in trans*. *Program and abstract book for 15<sup>th</sup> National Thalassemia Conference*, Charoensri Grand Hotel, Khon Khen, Thailand. April 22-24, 2009 (Poster presentation).
19. Thisarat Kusuwan, Tuangrath Sangpraypan & **Vip Viprakasit**. Evaluation of Patient's Satisfaction on Different Iron Chelation Therapies: What do They Prefer to Control Their Iron Overload? *Program and abstract book for 15<sup>th</sup> National Thalassemia Conference*, Charoensri Grand Hotel, Khon Khen, Thailand. April 22-24, 2009 (Poster presentation).
20. Suchada Riolueang, Supachai Ekwattanakit, **Vip Viprakasit**. Identification of significant epigenetic marks through methylation profile analysis of 105 clones of the G-gamma and A-gamma globin genes. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Oral presentation).
21. Jessada Buawbunnum & **Vip Viprakasit**. Are they really mild disease? A longitudinal analysis of growth & development in childhood Hemoglobin E/ $\beta^+$

- thalassemia. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Oral presentation).
22. Pornpun Sripornsawan, Bunchoo Pongtanakul, Kalaya Tachavanich, **Vip Viprakasit** Expected and unexpected adverse events due to deferasirox; a novel oral iron chelator, in pediatric patients with  $\beta$ -thalassemia. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Oral presentation and Best presentation award).
  23. Warangkana Thongnoppakun & **Vip Viprakasit**. Molecular epidemiology of *UGT1A1* mutations in Thailand. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Poster presentation).
  24. Pornpun Sripornsawan, Bunchoo Pongtanakul, Waraporn Glomglao, **Vip Viprakasit** Possible fatal consequence of febrile neutropenia in patients received deferiprone; A red-alert from prospective clinical evaluation for serious adverse events of deferiprone in Thai pediatric patients. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Poster presentation).
  25. Suchada Riolueang, Waraporn Glomglao, Vip Viprakasit First identification of a rare single nucleotide deletion (-A) of the translation initiation (ATG) codon of the  $\alpha$  2 globin gene in A Thai family. *Program and abstract book for 14<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand. June 25-27, 2008 (Poster presentation).
  26. Nunthana Siripipattanamongkol, Warangkana Thongnoppakun, Lavunlaya Inchgarm, Vipavee Tungtamniyom, Kriangsak Jirapaet & **Vip Viprakasit**. Molecular genetics of G-6-PD deficiency in Thai neonates with hyperbilirubinemia. *Program and abstract book for 65<sup>th</sup> National Pediatric Conference*, Holiday Inn Resort, Regent Beach, Chaum, Petchaburi, Thailand, April 23-25, 2008 (Oral presentation and selected for the “*Young Investigator Award*” for N. S.).
  27. Yuwarat Monteerarat, Kulkanya Chokephaibulkit, Prasert Auewarakul & **Vip Viprakasit**. Dissecting host genetic susceptibility related to sialic linkage modifying enzymes using *IN VITRO* knock down RNA interference suggests Neu5Aco $\alpha$ 2-3Gal $\beta$ 1-4 is the main receptor avain influenza (H5N1) used in humans. *Program and abstract book for 64<sup>th</sup> National Pediatric Conference*, Royal Cliff Beach Resort & Hotel, Pattaya, Chonburi, Thailand, October 24-26, 2007 (Oral presentation).
  28. Yuwarat Monteerarat, Orathai Piboonpocanun, Kleesabai Sanakit, Nualanong Visitsunthorn, Visith Thongboonkerd, Prakrit Vichyanond & **Vip Viprakasit**. Identification of a novel *IL7RA* mutation (444\_450InsA) caused marked reduction in CD127 expression from a cohort molecular analysis of severe combined immunodeficiency (SCID) in Thailand. *Program and abstract book for 64<sup>th</sup> National Pediatric Conference*, Royal Cliff Beach Resort & Hotel, Pattaya, Chonburi, Thailand, October 24-26, 2007 (Oral presentation).

29. Waraporn Glomglao, Worrawut Chinchang & **Vip Viprakasit**. Validation analysis of the newly developed single tube multiplex  $\beta$ -thalassemia arms-PCR in routine laboratory setting. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
30. Warankana Thongnoppakun & **Vip Viprakasit**. A preliminary analysis of *UGT1A1* gene polymorphisms on bilirubin metabolism in beta thalassemia patients Thailand. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
31. Kalaya Tachavanich **Vip Viprakasit**. A comparative analysis between “Mahidol HB E/thal” and “thalassemia international federation (TIF)” scoring criteria for clinical severity grading in haemoglobin E/ $\beta$  thalassemia. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
32. Nunthawut Chat-Uthai, Issra Songmahachai, Yonrawee Piyakom, Wiyakarn Utto, Lerluk Suwanthol & **Vip Viprakasit**. *IN VITRO* study of red blood cells osmotic fragility and acidic resistance in different thalassemia syndromes suggests role of red blood cell pathobiology underlying acute haemolytic crisis. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
33. Suchada Riolueang, Worrawut Chinchang & **Vip Viprakasit**. First identification of HB westmead (alpha 122 (H5) HIS-GLN) in two unrelated thaifamilies and its interaction with beta thalassemia. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
34. Thisarat Kusuwan, Lakha Pangnukroh, Wanida Leekamnerdthai, Tuangrat Sangpraypan<sup>2</sup> & **Vip Viprakasit**. Analysis of treatment complacance and related health and social determining factors in thai thalassemia patients under long-term deferrioxamine administration. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
35. Rungthip Chindathammanusan, Waraporn Glomglao & **Vip Viprakasit**. Comparative analysis on laboratory diagnosis of thalassemia and haemoglobin disorders between liquid chromatography and ISO-electric focusing in 1,168 thais. *Program and abstract book for 13<sup>th</sup> National Thalassemia Conference*, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).
36. Worrawut Chinchang, Suchada Riolueang & **Vip Viprakasit**. Identification of hemoglobin YALA;A novel beta thalassemia mutation due to thymidine deletion of codon 42 (-T) causing  $\beta^0$  thalassemia and its interaction with hemoglobine E. *Program*

and abstract book for 13<sup>th</sup> National Thalassemia Conference, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007 (Poster presentation).

37. **Vip Viprakasit**. Laboratory diagnosis for thalassemia. *Program and abstracts book for the 50<sup>th</sup> Anniversary Conference of Faculty of Associated Medical Technology 2007*, Impact Arena, Bangkok, Thailand, June 25-27, 2007 (invited speaker).
38. Worrawut Chinchang & **Vip Viprakasit\***. A single tube multiplex  $\beta$ -thalassemia ARMS-PCR: a new expedition of comprehensive molecular diagnosis of common  $\beta$ -thalassemia mutations found in Thailand. *Program and abstract book for the 34<sup>th</sup> Annual Meeting of The Thai Society of Hematology: Consultative Hematology*, Twin Tower Hotel, Bangkok, Thailand, March 12-15, 2007 (oral presentation)
39. Krongjit Lekpetch, Woraporn Glomglao, Wiyakan Utto, Klebsabi Sanpakit, Worrawut Chinchang, Voravarn S. Tanphaichitr & **Vip Viprakasit\***. A longitudinal analysis of clinical heterogeneity and disease severity in 145 pediatric patients with non-deletional Hemoglobin H disease. *Program and abstract book for the 34<sup>th</sup> Annual Meeting of The Thai Society of Hematology: Consultative Hematology*, Twin Tower Hotel, Bangkok, Thailand, March 12-15, 2007 (oral presentation)
40. Kalaya Tachavanich & **Vip Viprakasit\***. Development of a comprehensive red blood cell enzymopathy laboratory in Thailand and a preliminary study of normal activity range in 8 common erythroenzymes in Thais. *Program and abstract book for the 34<sup>th</sup> Annual Meeting of The Thai Society of Hematology: Consultative Hematology*, Twin Tower Hotel, Bangkok, Thailand, March 12-15, 2007 (oral presentation)
41. Yuwarat Monteerarat, Orathai Piboonpocanun, Klebsabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond & **Vip Viprakasit\***. Genetic heterogeneity underlying severe combined immunodeficiency (SCID) in Thai population and identification of a novel *IL7RA* mutation causing  $TB^+NK^+$  SCID. *Siriraj Medical Journal* 2007; 59: suppl. 1: OC005 (Presented as an oral presentation in the 46<sup>th</sup> Annual Siriraj Medical Conference, Thai Navy Convention Centre, Bangkok, Thailand, March 5-9, 2007).
42. Pairunyar Sawathiparnich, Linda Weerakulwattana, Pornpimol Kiattisakthavee, Katharee Chaichanwatanakul & **Vip Viprakasit**. Osteopenia is commonly present in prepubertal children with severe  $\beta$ -thal/Hb E despite adequate transfusion therapy. *Siriraj Medical Journal* 2007; 59: suppl. 1: OA004 (Presented as an oral presentation in the 46<sup>th</sup> Annual Siriraj Medical Conference, Thai Navy Convention Centre, Bangkok, Thailand, March 5-9, 2007).
43. Supachai Ekwattanakit, Worrawut Chinchang, Suchada Riolueang & **Vip Viprakasit**. Development of epigenetic analysis by determining CpG methylation profile to evaluate phenotypic heterogeneity in patients with thalassemia. *Program and abstract book for Annual BIOTEC Meeting*. Ekpilin Riverkeuw Hotel, Kanjanaburi, Thailand, October 26-28, 2006 (Poster presentation).

44. **Vip Viprakasit**. Common pitfalls in thalassemia diagnosis. *Program and Abstract Book of the 33<sup>rd</sup> National Scientific Conference: Hematology 2006: Common Pitfalls in Hematology*, Thailand Society of Hematology, Hilton Phuket Arcadia Resort & Spa, Phuket, Thailand, October 12-14, 2006 (invited speaker).
45. Yuwarat. Monteerarat, Orathai Piboonpocanun, KleebSabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visit Tongboonkerd, Pakit Vichayanond & **Vip Viprakasit**. Identification of a novel IL7RA mutation (444\_450 insA) caused marked reduction in CD127 expression from a cohort molecular analysis of severe combined immunodeficiency (T<sup>-</sup>, B<sup>+</sup>, NK<sup>+</sup> SCID) in Thailand. *Program and abstract book for Annual Thailand Research Fund Conference*, Regent Cha-Um Hotel, Petchaburi, Thailand, October 12-14, 2006 (Poster presentation).
46. S. Khositseth, A. Sirikanerat, K. Wongbenjarat, S. Opastirakul, S. Khoprasert, R. Peuksungnern, D. Wattanasirichaikul, W. Thongnoppakhun, **V. Viprakasit** & P. Yenchitsomanus. Distal renal tubular acidosis associated with anion exchanger 1 (AE1) mutations in Thai children. *Program and abstract book for Annual Thailand Research Fund Conference*, Regent Cha-Um Hotel, Petchaburi, Thailand, October 12-14, 2006 (Poster presentation).
47. W. Glomglao, W. Utto, W. Chantasigh, P. Umritt & **V. Viprakasit\***. Application of multiplex-GAP PCR analysis for seven common  $\alpha$  thalassemia deletions in routine laboratory service. *Program and abstract book for 12<sup>th</sup> National Thalassemia Conference*, Chalern Sri Grand Hotel, Udonthani, Thailand, May 24-26, 2006 (Poster presentation).
48. T. Sanpraypan, N. Sripiboonkit, K. Tachavanich, L. Suwantol & **V. Viprakasit\***. Patients' satisfaction on services provided at pediatric regular transfusion clinic, Siriraj hospital. *Program and abstract book for 12<sup>th</sup> National Thalassemia Conference*, Chalern Sri Grand Hotel, Udonthani, Thailand, May 24-26, 2006 (Poster presentation).
49. Y. Monteerarat, O. Piboonpocanun, K. Sanpakit, W. Chinchang, K. Tachavanich, N. Visitsunthorn, P. Vichayanond, **V. Viprakasit\***. Molecular analysis of severe combined immunodeficiency in Thailand. *Program and abstract book for 32<sup>th</sup> Annual Meeting of The Thai Society of Hematology*, Chalerm Pra Baramee Building, Bangkok, Thailand, March 26-29, 2006 (oral presentation).
50. Kalaya Tachavanich & **Vip Viprakasit\***. Rapid flow cytometric test using Eosin-5-Maleimide Assay (EMA) for the diagnosis of red blood cell membrane disorders. *Program and abstract book for 32<sup>th</sup> Annual Meeting of The Thai Society of Hematology*, Chalerm Pra Baramee Building, Bangkok, Thailand, March 26-29, 2006 (oral presentation) (oral presentation).
51. Jassada Buaboonnam, Krongjit Lekpetch, Worrawut Chinchang, **Vip Viprakasit\***. Do we need a prenatal diagnosis for our unborn baby? A further identification of Hb G-Makassar in Thailand presented as Hb S-like variant. *Program and abstract book for 32<sup>th</sup> Annual Meeting of The Thai Society of Hematology*, Chalerm Pra Baramee Building, Bangkok, Thailand, March 26-29, 2006 (oral presentation).

52. **Vip Viprakasit.** Genotype-phenotype interaction in paediatric patients with Hb H disease. *Update on Thalassemia Conference*, Royal City Hotel, Bangkok, Thailand, November 14, 2005 (invited speaker).
53. **Vip Viprakasit.** Current Approach in Paediatric Anemia. *Proceeding of the 37<sup>th</sup> National Paediatric Conference*, Cha-Um, Thailand, April 27-29, 2005 (invited speaker for a guest lecture on paediatric anemia).
54. Treesucon A, Sanpakit K, **Viprakasit V**, Theptaranon Y, Narkbunnam N and Veerakul G. Development of a multiplex RT-PCR for simultaneous detection of 5 fusion transcripts in childhood acute lymphoblastic leukaemia and Philadelphia-chromosome positive chronic myeloid leukaemia. *Program and Abstract Book of the 30th National Scientific Conference: Hematology 2005: State of the Art*, Thailand Society of Hematology, Bangkok, Thailand, March 7-10, 2005 (oral presentation).
55. **Vip Viprakasit**, Genotype-phenotype correlation in patients with  $\alpha$  thalassaemia *Proceeding of the 10th National Thalassemia Conference*, Bangkok, Thailand, July 29-30, 2004 (invited speaker in a symposium on genotype-phenotype in thalassaemia).
56. **Vip Viprakasit**, Worrawat Chinchang, Pipat Chotimarattana, Yingyong Chinthamitr, Parichat Pung-Amritt and Voravarn S. Tanphaichitr. Hb Woodville, a rare alpha globin variant, caused by codon 6 mutation of the alpha 1 gene. *Proceeding of the 10th National Thalassemia Conference*, Bangkok, Thailand, June 5-7, 2004 (oral presentation).
57. Worrawat Chinchang, Voravarn S. Tanphaichitr and **Vip Viprakasit** Successful molecular characterization in 280 Thai patients with Hb H disease. *Proceeding of the 10th National Thalassemia Conference*, Bangkok, Thailand, June 5-7, 2004 (oral presentation).
58. Kalaya Tachavanich, **Vip Viprakasit**, Worrawat chinchang, Waraporn Glomglaio, Parichat Pung-Amritt and Voravarn S. Tanphaichitr. Hematological phenotype of homozygous hemoglobin E with and without alpha thalassemia. *Proceeding of the 10th National Thalassemia Conference*, Bangkok, Thailand, June 5-7, 2004 (poster presentation).
59. **Vip Viprakasit**, Alison T. Merryweather-Clarke, Yingyong Chinthamitr, Lisa Schimanski, Somdet Srichairatanakool, Chanin Limwongs, Alain Townsend and Kathryn J. H. Robson. Molecular diagnosis of the first ferroportin mutation (C326Y) in the Far East causing a dominant form of inherited iron overload. *Proceeding of the 5<sup>th</sup> Princess Chulabhorn International Science Congress*, Bangkok, Thailand, August 16-20, 2004 (poster presentation).
60. Worrawat Chinchang, **Vip Viprakasit**, Parichat Pung-amritt, Lerlugsu Suwantol, Voravarn S. Tanphaichitr and Pa-thai Yenchitsomanus. Molecular diagnosis of Hemoglobin Dhonburi, an electrophoretically silent hemoglobin variant. Presented in the 43<sup>rd</sup> Siriraj Scientific Congress, Faculty of Medicine Siriraj Hospital, Thailand, March 3-7, 2003 (oral presentation).
61. W. Chinchang, **V. Vipraksit**, P. Pung-amritt, T. Sangpraypan and V.S. Tanphaichitr. The first identification of compound heterozygosity of a rare  $\beta$ -globin initiation codon



- mutation (ATG→AGG) and Hb E causing severe phenotype in a Thai patient. *Proceeding of the 9th National Thalassemia Conference*, Bangkok, Thailand, May 5-6, 2003 (oral presentation).
62. Tanphaichitr VS, **Viprakasit V**, Veerakul G, Assteerawatt A, Tachavanich K, Songpraypan T and Suvatte V. Iron Chelation in Thalassemic Patients. *Proceeding of the 7th National Thalassemia Conference*, Bangkok, Thailand, 2001 (oral presentation).
63. Tanphaichitr VS, Chokephaibulkit K, Viprakasit V, Suwantol L, Veerakul G, Kankirawatana S. Adverse reactions after 23-valent Pnuemococcal Polysaccharide Vaccination Among Thai Thalassemic Children. *Proceeding of the 6th National Thalassemia Conference*, Bangkok, Thailand, 2000: p-13 (oral presentation).
64. Tanphaichitr VS, **Viprakasit V**, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G, Kankirawatana S, Pung-Amritt P and Suvatte V. Iron chelating; experience in paediatric patients at Syria Hospital. *Proceeding the 4<sup>th</sup> national conference of Thalassemia*, Chiang Mai, Thailand 1998.
65. **Viprakasit V** and Rangsiyanond P. Hearing impairment in high-risk neonates. *Proceeding of the 3<sup>rd</sup> National Congress of Perinatology*, Bangkok, Thailand 1996.

## BOOK AND BOOK CHAPTERS (in English)

**Vip Viprakasit** & Worapant Kriengsoontornkit. Metal Antagonists (Iron Chelator) in Side Effects of Drugs, Annual, 35, Chapter 23; 419-433

Ali Taher, Elliott Vinchinsky, Khaled Musallam, Maria Dominica Cappellini, **Vip Viprakasit**. Guidelines for The management of Non Transfusion Dependent Thalassaemia (NTDT). Thalassaemia International Federation (TIF), Nicosia, Cyprus, 2013.

Maria D. Cappellini, Alan Cohen, John Porter, Ali Taher, **Vip Viprakasit**, editors. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Thalassaemia International Federation (TIF), Nicosia, Cyprus, 2014.

## BOOK CHAPTERS (in Thai)

**Vip Viprakasit**. Molecular Basis of Neonatal Hyperbilirubinemia. In: Soogsawang J Limprayoon G, Nguengchum S, Sanpakit & Kolatat T. editors. New Frontier in Pediatrics. 1<sup>st</sup> ed. Bangkok (Thailand): The How Can Do Co. Ltd. 2008. p 20-32.

**Vip Viprakasit**. Inherited Bone Marrow Failure Syndrome: An Update. In: Soogsawang J Limprayoon G, Nguengchum S, Sanpakit & Kolatat T. editors. New Frontier in Pediatrics. 1<sup>st</sup> ed. Bangkok (Thailand): The How Can Do Co. Ltd. 2008. p 229-241.

**Vip Viprakasit**. Update on molecular genetics of thalassemia in Thailand. In: Sanansilpa W. *et al.* editors. Excellent Medical Practice with Sufficiency Economy. 1<sup>st</sup> ed. Bangkok (Thailand): The P.A. Living Co. Ltd. 2007. p 275-86.

**Vip Viprakasit**. Acute anemia. In: Soogsawang J., Auengpreang P., Wisuthseriwong W., Srisuparo P. and Limprayoon G. editors. The Essentials in Pediatric Emergency. 1<sup>st</sup> ed. Bangkok (Thailand): The How Can Do; 2006. p 185-195.

**Vip Viprakasit**. Thalassaemia diagnosis. In: Prayoonwiat V. editor. Common Pitfalls in Hematology. 1<sup>st</sup> ed. Bangkok (Thailand): Thailand Society of Hematology; 2006. p 88-104.

## BOOKLETS

**Vip Viprakasit**. Clinical Practice Guideline for Deferiprone in Patients with Iron Overload. 1<sup>st</sup> ed. Bangkok, Government Phamaceutical Organization (GPO) 2009; p 1-34.

**Vip Viprakasit & Thisarat Kusuwan**. Handbook for Blood Transfusion in Thalassaemia 1<sup>st</sup> ed. Bangkok, Media-Mate Publ. Co. Ltd. 2009; p 1-45.

**Vip Viprakasit**. IPD vaccine for thalassaemia patient. 1<sup>st</sup> ed. Bangkok, Media-Mate Publ. Co. Ltd. 2008.; p 1-12.

**Vip Viprakasit**. 10 Steps for oral chelation therapy-A focus on deferasirox. 1<sup>st</sup> ed. Bangkok (Thailand), Media-Mate Publ. Co. Ltd. 2007; p1-24.

**Vip Viprakasit**. 10 Steps for oral chelation therapy-A focus on deferiprone. 1<sup>st</sup> ed., Bangkok (Thailand), Media-Mate Publ. Co. Ltd. 2007; p1-24.

**Vip Viprakasit**. What is Thalassaemia Carrier. 1<sup>st</sup> ed. Bangkok (Thailand), Media-Mate Publ. Co. Ltd. 2007; p1-12.

**Vip Viprakasit.** How to maximize efficacy of desferioxamine therapy. 1<sup>st</sup> ed. Bangkok (Thailand), Media-Mate Publ. Co. Ltd. 2007; p1-12.

**Vip Viprakasit.** An update on iron chelation therapy. 1<sup>st</sup> ed. Bangkok (Thailand), Media-Mate Publ. Co. Ltd. 2006; p1-12.

**PUBLICATION IN POPULAR SCIENCE JOURNALS (In Thai)**

1. **Vip Viprakasit.** “When you have thalassemia gene”. *SciMag*, 2007; 4(5); 29-30.
2. Noppadol Sirithanarattanakul & **Vip Viprakasit.** “Iron overload management”. *Clinics*, 2007; 23 (7); 568-9.
3. **Vip Viprakasit.** “Ecchymosis in your kid, what should you do”. *Ruklook*, 2005; 273(10); 174-5.

**INVITED CHAIR-PERSON**

1. Meeting-chairman: 2012 EGM Iron Summit. Langham Place Hotel, Hong Kong, 22-23 September 2012.
2. Co-chairman session: Update on Paroxysmal Nocturnal Hemoglobinuria. The Second ASEAN Federation of Haematology Scientific Congress. The Waterfront Conference Center, Grand Copthorne Waterfront Hotel, Singapore, 8 September 2012.
3. Invited faculty: Non-Transfusion Dependent Thalassemia (NTDT) Severity Scoring Index. The Thistle Kingsley Hotel, London, UK, 31 July 2012.
4. Thalassemia International Federation (TIF) delegation visit to Indonesia, Jakarta from 31 May-4 June 2012.
5. Co-chairman session: Free paper 11 (hematology-Oncology), The 8th Congress of Asian Society for Pediatric Research, Sheraton Grande Walkerhill Hotel, Seoul, Korea, 17-19 May 2012.
6. Invited faculty: Non-Transfusion Dependent Thalassemia (NTDT) Communication Advisory Board. Sofitel Heathrow Hotel, London, UK, 28 November 2011.
7. Meeting-chairman: Thalassaemia & Sickle Cell Iron Summit: Hyatt Regency Hotel, Dubai, United Arab of Emirates, 9 April 2011.
8. International scientific advisory and local organizing committee for The First Pan-Asian Conference on Haemoglobinopathies, Royal Orchid Sheraton, Bangkok, Thailand, 8-10 February 2012.
9. International scientific advisory committee for 12<sup>th</sup> International Conference on Thalassaemia and the Haemoglobinopathies, WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011.
10. Advisory board member on thalassemia, Indian Society of Hematology, ITC Grand Central Hotel, Parel, Mumbai, India, 29 May 2011
11. Advisory board member on MRI LPI Assessing the role of cardiac MRI, LPI, and deferasirox blood level testing in IOL monitoring in clinical practice, Baltimore Hotel, Paris, France, 11 January 2011
12. Advisory board member on deferasirox, Marina Mandarin Hotel, Singapore, 7 October 2008
13. Co-chairman session: Simultaneous symposia 10: Free Paper Presentation. The Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics. The Shangri-la Mactan Island Resort, Mactan Island, Cebu, Philippines, 3 April 2008.

14. Co-chairman session: Symposium on Hearing Impairment. The 6<sup>th</sup> Asia Pacific Regional Meeting of the International Society of Neonatal Screening. Furama Hotel, Singapore, 1 September 2007.

15. Advisory board member on iron overload in thalassemia intermedia. The Asia Pacific Summit-New Horizon in Treating Hematological Diseases-translating science, building alliance 2007. Jeju Island, South Korea, 5 July 2007.

## **INVITED SPEAKER**

### **International speaker**

1. “Optimal Iron Chelation” and “Management of Thalassaemia Intermedia” 7<sup>th</sup> Thalassaemia Workshop for doctors, nurses and health personannel. Ambulatory Care Center, Hospital Pulau Pinang, 8 October 2012.

2. “Tissue iron monitoring” in Standards of care II symposium, “Genotype-phenotype correlation in thalassaemia” in Translating research to clinical care symposium. “Optimising quality of life” in Meet the expert session and “Country report on prevention and control program for severe thalassemia syndrome” 5<sup>th</sup> National Thalassaemia Seminar for Patients, Parents and Professionals “Optimising quality of life”, Ministry of Health, Malaysia, Sunway Putra Hotel, Kuala Lumpur, 6-7 October 2012.

3. “Pathophysiology and the complications of iron overload across anemias”, “Review of the physiology, diagnosis and management of  $\beta$ -thalassemia major” and “Panel discussion: 5-years n practice with deferasirox”. The 2012 EGM Iron Summit, Langham Place Hotel, Hong Kong, 22-23 September 2012.

4. “Haemoglobinopathies in 2012”. The 2012 Australia Institute of Medical Scientist (AIMS) Natinal Scientific Meeting (NSM), Darwin Convention Center, Darwin, Australia, 24-27 September 2012.

5. “Hb E thalassemia Syndromes: How to diagnose and manage these patients” and “Novel/rare causes of congenital non-immune hemolytic anemia”. The Second ASEAN Federation of Haematology Scientific Congress. The Waterfront Conference Center, Grand Copthorne Waterfront Hotel, Singapore, 7-8 September 2012.

6. The 6<sup>th</sup> Prof. Alendry P. Caviles Jr. Memorial Lecturer on the topic; “Thalassemia Screening in Developing Countries” for the Philippine Society of Hematology and Blood Transfusion (PSHBT)’s 42<sup>nd</sup> Annual Convention, Crown Plaza Manila Galleria, Oritigas Avenue, Asian Develoment Ave., Quezon City, Philippines, 4 September, 2012.

7. “Non-transfusion dependent thalassemia (NTDT) in Asia” in Haematology Stream: Advances in Management of Thalassaemia and Multiple Myeloma. Novartis Oncology Asia Pacific Summit 2012, Inter Continental, Kuala Lumpur Hotel, Kuala Lumpur, Malaysia, July 8, 2012.

8. “Prevention and control program for severe thalassemia syndromes in Thailand” A Join-Official Visit Seminar between National Institute of Hematology and Blood Transfusion (NIHBT) and Faculty of Medicine Siriraj Hospital, Auditorium room, NIHBT, Hanoi, Vietnam, 22 June 2012.

9. “Caring for your NTDT patient: interactive case study in Satellite Symposium “Beyond thalassemia major: what’s new in non-transfusion –dependent thalassemia (NTDT)” at the 17<sup>th</sup> Congress of the European Hematology Association (EHA), Amsterdam RAI, Amsterdam, The Netherlands, 14 June 2012.

10. “Variable clinical phenotypes and management outcomes in patients with KLF-1 mutations” 18<sup>th</sup> Annual Conference on Hemoglobin Switching, The Asilomar Conference Center in Pacific Grove, Monterey, California, USA, 7-11 June 2012.

11. “Global epidemiology of  $\beta$ -, Hb E,  $\alpha$ -thalassemia and SCD with specific reference to Asia and its emerging health problem. The 8<sup>th</sup> Congress of Asian Society for Pediatric Research. Sheraton Grande Walkerhill Hotel, Seoul, Korea, 17-19 May 2012.

12. “Clinical complications in Hb E/ $\beta$  thalassemia” Global Iron Summit 2012, Maritim Hotel, Berlin, Germany, 17-18 March 2012.

13. The Keynote lecture on “Epidemiology and Background & Thalassemia intermedia”. The Master-class for Adult Thalassemia and Haemophilia Nursing 2012 organized by World Federation of hemophilia and Thalassemia International Federation, Hospital Authority Headquarter, Hong Kong SAR, 26 – 28 February 2012.

14. “Treatment of  $\alpha$ -thalassemia-Hb H disease” and “Global epidemiology of  $\beta$ -, Hb E,  $\alpha$ -thalassemia and SCD with specific reference to Asia” The First Pan-Asian Conference on Haemoglobinopathies, Royal Orchid Sheraton, Bangkok, Thailand, 8-10 February 2012.

15. “Clinical phenotypes and molecular pathology of common thalassaemia and haemoglobinopathies in the Far East” Department of hematology, School of Medicine, Cardiff University, Cardiff, UK, 26 January 2012.

16. “Clinical trial on deferiprone in Thailand” Red cell disorder unit seminar, Department of hematology, University College of London, UK, 25 January 2012.

17. “Update on thalassemia and hemoglobinopathies: From bench to bedside”. In Symposium 1: Haemoglobinopathies in the Haematology Society of Australia and New Zealand, Australia and New Zealand Society of Blood Transfusion and Australian Society of Thrombosis and Haemostasis (HAA) 2011 Sydney Australia with XIIth Congress of the International Society of Hematology Asia-Pacific Division. 30 October-2 November 2011.

18. “State of the Art Treatment for Hemoglobin Disorders” Program for Health Professionals, Edsa Sheangi- La Hotel, Santan Room and Program for Patients/Parents Workshop by Thalassemia International Federation (TIF). Opal Room, Millenia Suites 8001 Jose Maria Escrivá Drive, Ortigas Center, Pasig city, Philippines, 3-4 September 2011.

19. “The role of iron chelation therapy in iron overload patients” 2011 Chinese Medical Association-Taipei & Taiwan Society of Cancer Palliative Medicine Combined Annual Meeting, Taiwan Veterans General Hospital, Taipei, 26 June 2011 and at Southern Taiwan Hematology Expert Meeting, Shangri-La’s Far Eastern Plaza Hotel, Tainan, 27 June 2011 and at Central Taiwan Hematology Expert meeting, Windsor Hotel, Taichung, 28 June 2011.

20. “Iron chelation in Medical Panel: Overview/ Summary and Questions & Answers.” “Clinical complications in thalassaemia intermedia in Non-Transfusion Dependent Thalassemia Revisited 2011 symposium” and “Heterogeneity in the Clinical Severity of HbH Disease” in the Alpha-thalassemia symposium. 14<sup>th</sup> International TIF Conference for Thalassaemia Patients and Parents and 12<sup>th</sup> International Conference on Thalassemia and the Hemoglobinopathies. WOW Hotels Topkapı & Kremlin Palace – Antalya, Turkey, 11-14 May 2011.

21. “Cardiac outcomes in thalassemia and Asia Pacific Iron Academy T2\* network” and “Update on Iron Chelation therapy in Thalassemia Major” The Indian Iron Summit, Mumbai, 20-21 May 2011.

22. “A geneticist’s perspective Hemoglobinopathies and Thalassemias; different perspectives” 2011 AACC (American Academy of Clinical Chemistry) Annual Meeting, Georgia World Congress Center, Atlanta, Georgia, July 24 – 28, 2011.

23. “Chelation therapy and goals of treatment in  $\beta$ -thalassemia major.” Australian Iron Summit 2011, Intercontinental Hotel, Sydney, Australia, 29 May 2011.

24. “Practical challenges on the management of patients with thalassaemia major” and “Thalassemia” 2011 HSANZ Queensland State Meeting, State Library of Queensland, Southbank, Brisbane, Australia, 25-26 March 2011.

25. “Management of Hb E/ $\beta$  thalassaemia” Global Iron Summit 2011, The Swissôtel The Bosphorus, Istanbul, Turkey, 11-12 March, 2011.

26. “Real time PCR and high resolution melt analysis (HRM) application for prenatal diagnosis of thalassaemia: A pre-congress workshop on laboratory diagnosis of thalassaemia”, “Molecular basis of beta-thalassemia in Symposium2; Molecular biology of thalassaemia”, “Management of thalassaemia in Meet-the-expert” and “Impact of iron removal across diseases in Symposium 8: Basic science of iron toxicities”. The 3<sup>rd</sup> International Conference on Thalassemia in China & The 2<sup>nd</sup> Asia Pacific Iron Academy (APIA) Conference, Guangxi Wharton International Hotel, Nanning, Guangxi, P. R. China, 3 – 6 November 2010.

27. “Standard of care: Genotype phenotype & Iron Chelation: Is there an optimal strategy”. The 5<sup>th</sup> Thalassaemia workshop for doctors, nurses and health personnel, Penang General Hospital, Penang, Malaysia, 4 October 2010.

28. “Types of Thalassaemia & Chelation Therapy”. The 15<sup>th</sup> Thalassaemia Camp, Penang Thalassemia Society, Hotel Cititel, Penang, Malaysia, 2-3 October 2010.



29. “Thalassemia & Hemoglobin disorders in the next decade: Evolving diagnosis and treatment”. National Congress on Hematology & Blood Transfusion 2010, National Institute of Hematology and Blood Transfusion, Hanoi, Vietnam, 22 Sep 2010.

30. “Mutations in the EKLK Gene Lead to an Unexpectedly Severe Phenotype in a Family with Thalassaemia”. Quick Fire Session in the 17<sup>th</sup> Hemoglobin Switching Conference, St. John’s College, Oxford, UK, 2-6 September, 2010.

31. “Overview of cardiac iron overload in patients receiving chronic transfusions: presentation, diagnosis and treatment options” Thailand Iron Summit 2010. Millennium Hilton Hotel, Bangkok, Thailand, 25 August 2010

32. “Laboratory diagnosis of alpha-thalassaemia” and “Thalassaemia screening program: Thailand Experience”. Workshop on Laboratory diagnosis of thalassaemia and haemoglobin variants: updates and pitfalls in diagnosis, Department of Pathology-Haematology, Hospital Kuala Lumpur & Ministry of Health Malaysia. Auditorium National Blood Services Centre, Kuala Lumpur, 23 July 2010

33. “Update on developments in management of cardiac iron overload in patients with thalassaemia” Indonesia Iron Summit 2010, 3 July 2010, Hotel Meliá Purosani, Yogyakarta, Indonesia, 3 July, 2010

34. “Update on developments in management of cardiac iron overload in patients with thalassaemia” Taiwan Iron Summit 2010, Shangri-La Far Eastern Plaza Hotel, Taipei, Taiwan, 27 June, 2010

35. “Update on CORDELIA study (2206)”. Deferasirox Investigator Meeting Hotel Meliá Barcelona, Barcelona, Spain, 10 June 2010

36. “Chelation therapy and goals of treatment in  $\beta$  thalassaemia major” The Ingueral Australian Iron Academy 2010. Intercontinental Hotel, Sydney, Australia, 29 May 2010.

37. “Optimal management of iron toxicity”. Iron Overload Case Study Forum 2010. Grand Prince Hotel Akasaka, Tokyo, Japan, 22 May 2010.

38. “What is the role of iron chelation therapy in  $\beta$ -thalassaemia intermedia?” Global Iron Summit 2010, Hilton Hotel, Prague, Czech Republic, 10 & 11 April 2010.

39. “Understanding Thalassemia & Hemoglobin Variants-HPLC and molecular point of view” and “Workshop on Thalassaemia Diagnosis” in The 7<sup>th</sup> Thal user meeting - Bio-Rad India 2010. Mumbai, Kolkata and Delhi, 12-14 March 2010.

40. “Recent update of iron chelators” Peer to Peer Meeting for Thalassaemia. Indonesian Pediatrician Haematologist Working Group. JW Marriott Hotel, Medan, Indonesia, 22 Feb 2010.

41. "Hereditary disorders of iron metabolism: Asian perspective" and "A novel form of iron deficiency anemia refractory to oral iron therapy". The First Asia-Pacific Iron Academy (APIA)-Conference 2009: Iron in Health and Diseases. The Shangri-La Hotel, Chiang Mai, Thailand, November 26-29, 2009.

42. "An Overview of Thalassaemia Care in the Asia-Pacific", The Malaysian Thalassaemia Registry Meeting, The Malaysian Society of Paediatric Haematology and Oncology (MASPHO), Corus Paradise Hotel, Port Dickson, Negeri Sembilan, Malaysia, October 31<sup>st</sup>, 2009.

43. "Optimising iron chelation therapy", "Alpha Thalassaemia", "Challenges in thalassaemia management in the developing country" and "The alpha thalassaemia syndrome". 4<sup>th</sup> Thalassaemia Workshop, Penang Hospital and 13<sup>th</sup> Thalassaemia Camp, The Hospital Pulau Pinang and Pulau Pinang Thalassaemia Society, Malaysia, October 17-18, 2009.

44. "Treatment of iron overload in pediatric thalassemia: Experience and data from Thailand" Thailand Iron Summit 2009, Novartis Oncology: Asia-Pacific. Centara Grand Hotel, Bangkok, Thailand, July 8<sup>th</sup>, 2009.

45. "Recent advances in Iron Chelation Therapy in Thalassaemia Major" The East Malaysia Thalassaemia Forum, The Malaysian Paediatric Association, Sutera Harbour Resort, Kota Kinabalu, Malaysia, June, 13<sup>th</sup>, 2009.

46. "Recent studies on Chelation Therapy in Thailand" The NIH-NHLBL/NIDDK Workshop on Thalassemia: Clinical Priorities and Clinical Trials. Fishers Lane Conference Center, Rockville, MD, USA, May 20-21, 2009.

47. "Case-discussion: Optimal dosing of iron chelation therapy in Optimizing management of iron toxicity in thalassemia", Global Iron Summit, Excerpta Medica, Hilton London Metropole, April 4-5, 2009.

48. "Treatment with deferasirox (EXJADE) in various anemias" Current Status and Problems of Global Clinical Trials: Progress in Hematology-2009" 5<sup>th</sup> General Assembly Asian Hematology Association-2009, Kobe Portopia Hotel, Kobe, Japan, February 13-14, 2009.

49. "Panel of Expert Discussion" in Thalassemia major expert lunch symposium at American Society of Hematology Meeting, Grand Hyatt Hotel, San Francisco (CA), USA, December 6, 2008.

50. "Molecular basis of thalassaemia - screening strategy in The Pre-Congress Workshop on Diagnosis of Thalassaemia - Laboratory Methods, Molecular Basis and Screening Strategy", "Hb H disease: A wide spectrum of clinical severity"; Symposium on Alpha Thalassaemia, "Geographic distribution and heterogeneity of alpha thalassemia; Symposium on Thalassemia Epidemiology" and "Hb E and thalassemia intermediate" and Meet the Expert Session. The 11<sup>th</sup> International Conference on Thalassemia & Hemoglobinopathies and 13<sup>th</sup> International TIF Conference for Thalassemia Patients & Parents (International Thalassaemia

Conference 2008), Suntec Singapore International Convention & Exhibition Centre, Singapore, October 8-11, 2008.

51. "Optimal Management of iron overload in Thalassemia and Other Anemias". 38<sup>th</sup> Annual Convention The Philippine Society of Hematology and Blood Transfusion: Hematology and Transfusion Medicine: Current Status and Future Perspectives, Edsa Shangri-La Hotel, Mandaluyong City, The Philippines, September 8-10, 2008.

52. "Clinical and laboratory diagnosis of thalassemia", "Iron chelation: Past, Present & Future", "Genotype-phenotype correlation in thalassemia" and "Improving quality of life for thalassemia patients". 3<sup>rd</sup> National Thalassemia Seminar and Clinical Course in the Management of Thalassemia, Berjaya Time Square Hotel & Convention Centre, Kuala Lumpur, Malaysia, May 26-29, 2008.

53. "The Challenge of Managing Thalassemia & New Insights in Iron Chelation"; Symposium on Thalassemia-Where are we now? Hong Kong Society for the Study of Thalassemia. Casablanca, 27<sup>th</sup> fl., The Park Lane Hotel, Causeway Bay, Hong Kong, May 8, 2008.

54. "Iron overload, practical management & current recommendation" and "The new era of iron overload" 3<sup>rd</sup> National Congress of Blood Transfusion and Hematology. Nha Trang, Vietnam, April 17-18, 2008.

55. "Pharmacogenomics in childhood malignancy"; Symposium session on Pharmacogenomics in Clinical Genetics. Joint 7<sup>th</sup> Human Genome Organization (HUGO)-Pacific Meeting and the 8<sup>th</sup> Asia-Pacific Conference on Human Genetics. Shangri-la Mactan Island Resort, Cebu, Philippines, April 2-5, 2008.

56. "Hb E/ $\beta$  thalassemia-update on management" A special lecture for The KK Women's and Children Hospital of Singapore, March 14, 2008.

57. "Thalassemia: A view from Thailand as the hotspot, and the beckoning of a new dawn"; NUH Grand Round. The National University Hospital of Singapore, March 14, 2008.

58. "Update in the management of iron overload" An interactive case-studies workshop. Singapore Society of Hematology and Novartis Oncology, Singapore. Conrad Centennial Singapore Hotel, Singapore, March 13, 2008.

59. "Study design and research ethical issues and strategies for genetic epidemiology of influenza"; Genetic epidemiology of Influenza: A multinational pediatric initiative planning meeting. Delta Chelsea Hotel and The Hospital for Sick Children, Toronto, Canada, September 14-15, 2007.

60. "Genetic abnormalities in G6PD"; Symposium IX on G6PD Deficiency. The 6<sup>th</sup> Asia Pacific Regional Meeting of the International Society of Neonatal Screening. Furama Hotel, Singapore, August 29<sup>th</sup> - September 1, 2007.

61. “Thalassemia intermedia-pathophysiology and complications”; Session IV: Thalassemia-Future of Iron Chelation Therapy. The Asia Pacific Summit-New Horizon in Treating Hematological Diseases-translating science, building alliance 2007. Jeju Island, South Korea, July 6-9, 2007 (invited speaker)

62. “Evolving treatment paradigms in hematology”. The 2007 Hematology Forum of the Philippine Society of Hematology and Blood Transfusion. Taal Vista Hotel, Tagaytay, The Philippines, March 2, 2007.

63. “Variant thalassemia syndrome and therapeutic aspect”. Thalassemia Intermedia Advisory Board Meeting. Ambasciatori Palace Hotel, Rome, Italy, March 20, 2007.

64. “Gene therapy in thalassemia” The 4<sup>th</sup> Annual Meeting of Asian Hematology Association (AHA). Hilton Park-Nai Lert Hotel, Bangkok, Thailand, February 25, 2007.

65. “Thalassemia management: Physician Panel” The Exjade Asia Pacific Internal Launch Meeting. Grand Hyatt Aerawan Hotel, Bangkok, Thailand, May 16, 2006.

### **Local speaker**

1. “Hereditary disorders of iron metabolism”: SIBC 603: Biochemistry of Disease, Department of Biochemistry, Faculty of Medicine Siriraj Hospital, February 16, 2009.

2. “Gene Therapy”. 6<sup>th</sup> ASH Refresher Course for Hematologists, The Thailand Society of Hematology, Spring Field Resort & Spa, Cha-Um, Thailand, January 16-17, 2010.

3. “Thalassemia in New Era” Update in Pediatrics 2009, Sawanpracharak Hospital, Nakornsawan, November 20, 2009.

4. “Review on red cell membrane disorder” The Haematology/Oncology Course for Pediatric Residents, Vajira Medical college, Bangkok, Thailand, November 17, 2009.

5. “Thalassemia Diagnosis” Training course and Workshop for prevention and control programme for severe thalassemia, Siriraj Thalassemia Programme Project, Department of Research and Development, Faculty of Medicine Siriraj Hospital, June 17-19 and November 18-20, 2009.

6. “Iron chelation therapy in Thalassemia and GOOD-SMP programme for GPO-L-ONE”, Pratumthani Hospital, November 13, 2009.

7. “Iron chelation therapy in Thalassemia and GOOD-SMP programme for GPO-L-ONE” for 14 Southern Regional Hospitals, J. B. Hotel, Hat Yai, November 3, 2009.

8. “Update on thalassaemia management” First Siriraj Thalassaemia Seminar, Faculty of Medicine Siriraj Hospital, October 9, 2009.

9. "Current Clinical Practice on Thalassemia Management" Training and Workshop for Noreastern Thalassemia, Khon Khen Hospital, September 24-25, 2009.

10. "Thalassemia disease and Iron chelation therapy in Thalassemia Patients" Maharaj Nakornsrihammaraj Hospital, September 4, 2009.

11. "Thalassemia", Bhumiphol Adulyadej Hospital, August 7, 2009.

12. "Update in Pediatrics" Join Conference in Medical Sciences 2009 by Faculty of Medicine Siriraj Hospital, Mahidol University and Faculty of Medicine, Chulalongkorn University. Centara Grand Hotel, Bangkok, July 24, 2009.

13. "GLO-L-ONE: A New Dawn of Thai Thalassemic Patients: Luncheon Symposium", The 15<sup>th</sup> National Thalassemia Conference, Charoen Sri Grand Hotel, Khon Khen, Thailand, April 22-24, 2009.

14. "Understanding genetic association study in common pediatric problems" The 67<sup>th</sup> Annual Thailand National Pediatric Conference, The Zign Hotel, Pattaya, Chonburi, Thailand, April 9-11, 2009.

15. "CBC interpretation and common problems in hematology": Introduction to haematology/oncology course for pediatric residents, Vajira Medical college, Bangkok, Thailand, March 20, 2009.

16. "Recent advance of Iron Chelation therapy; Long term efficacy and safety of deferasirox 4.7 years". Corporate Symposium 3: "Problem-Oriented Hematology: 36<sup>th</sup> Annual Meeting of The Thailand Society of Hematology", Anoma Hotel, Bangkok, Thailand, March 16-19, 2009

17. "Red Cell Disorders: Clinical Approach to Red Cell Enzymopathy: Symposium 1". "Problem-Oriented Hematology: 36<sup>th</sup> Annual Meeting of The Thailand Society of Hematology", Anoma Hotel, Bangkok, Thailand, March 16-19, 2009

18. "Comprehensive care for thalassaemia", Basic Nursing Care Program for Thalassemia Patients, Siriraj Thalassemia Research Network, Faculty of Medicine Siriraj Hospital, Mahidol University, March 1st, 2009, Pullman King Power Hotel, Rangnum, Bangkok.

19. "Red cell membrane diseases". Department of Biochemistry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, February 27, 2009.

20. "Stem cells, What's Here and What's Next", Annual Meeting of Dermatological Society of Thailand, Centara Grand Hotel, Bangkok, Thailand, February 26, 2009.

21. "Disease of blood and blood forming organs-I". Intensive Review in Pediatrics by The Royal College of Pediatrics of Thailand, Pramongkutkoal Hospital College of Medicine, Bangkok, Thailand, February 18-21, 2009.

22. "Hemoglobin/Red cell-Epigenetics". 5<sup>th</sup> ASH Refresher Course for Hematologists, The Thailand Society of Hematology, Rayong Resort, Rayong, Thailand, January 17-18, 2009
23. "Molecular genetics in Kawasaki Disease"; Update on Kawasaki Disease, The Thailand Society of Pediatric Cardiology Meeting, Siam City Hotel, Bangkok, Thailand, November 23, 2008.
24. "Thalassemia". Lecture tour, Faculty of Medicine, Thammasat University, Pratumthani, Thailand, November 11, 2008.
25. "CBC; When to Order and How to Interpret the CBC count". The 66<sup>th</sup> Annual Thailand National Pediatric Conference, Centara Grand & Bangkok Convention Center at Central World, Bangkok, Thailand, October 3, 2008.
26. "Thalassemia", Lecture tour, Prananklow General Hospital, Pratumthani, July 8, 2008.
27. "Recent advance in thalassemia management", Lecture tour, Lumpang Regional Hospital, Lumpang, June 20, 2008.
28. "Thalassemia" Staff-training session, Wyeth Co. Ltd. Silom Building, Bangkok, August 29, 2008.
29. "Clinical experience on deferiprone: significant adverse events". Investigator Meeting on GPO-L-ONE<sup>®</sup> VMI initiative study organized by Government Pharmaceutical Organization (GPO), Miracle Grand Hotel, Bangkok, Thailand, August 29, 2008.
30. "Diamond Blackfan Anemia (DBA) in pregnancy". Department of Obstetrics and Gynaecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, July 25, 2008.
31. "Update on molecular genetics of Thalassemia in central Thailand" and "Interactive workshop on oral iron chelation therapy in Thalassemia". The 14<sup>th</sup> National Thalassemia Conference, Miracle Grand Hotel, Bangkok, Thailand, June 25-7, 2008
32. "Phase III-Clinical study for deferiprone" and "Clinical experience on deferiprone: Pediatric aspects". Investigator Meeting on GPO-L-ONE<sup>®</sup> Clinical Trial A001 organized by Thalassemia Foundation of Thailand, Rose Garden Hotel, Nakorn Prathom, Thailand, May 25, 2008.
33. "Update on pharmacogenetics in cancer therapy". Lecture tour, Tumour Center, Bhumipoladulyadej Hospital, Bangkok, Thailand, May 13, 2008.
34. "Update on oral chelation therapy". The 7<sup>th</sup> Annual Meeting for World Thalassemia Day, Thalassemia Foundation of Thailand, Pramongkutkoal Hospital College of Medicine, Bangkok, Thailand, May 11, 2008.

35. “Emerging roles of Exjade in Thalassemia”. Novartis Hematology Day; **Glivec Exjade Tasigna Together**, Hyatt Regency, Hua Hin, Petchaburi, Thailand, May 3-4, 2008.
36. “Chelation in the context of the latest iron science”. Symposium session on Managing Iron Overload to Improve Patient Outcomes. The 65<sup>th</sup> Thailand National Pediatric Conference, Holiday Inn Resort, Regent Beach, Chaum, Petchaburi, Thailand, April 23-25, 2008
37. “Management of hematologic malignancy and invasive fungal infections”. Staff-training session, Schering-Plough Co. Ltd. Rajanakarn Building, Bangkok, Thailand, April 8, 2008.
38. “How to approach Non-Hb Bart’s hydrops fetalis”. Obstetrics & Gynecology Conference, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, March 28, 2008.
39. “Molecular Basis of Neonatal Hyperbilirubinemia”. The 47<sup>th</sup> Annual Siriraj Medical Conference; A New Era of Best Practice and Innovation, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, March 17-19, 2008.
40. “Inherited Bone Marrow Failure Syndrome: An Update”. The 47<sup>th</sup> Annual Siriraj Medical Conference; A New Era of Best Practice and Innovation, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, March 17-19, 2008.
41. “Disease of blood and blood forming organs-I”. Intensive Review in Pediatrics by The Royal College of Pediatrics of Thailand, Pramongkutkoal Hospital College of Medicine, Bangkok, Thailand, March 3-7, 2008.
42. “Update on molecular genetics of iron metabolism”. Refresher Course for Haematologist: Update on Hematology-4, Thailand Society of Hematology, Royal Hill Golf Club Resort & Spa, Nakorn-nayok, Thailand, March 1-1, 2007.
43. “Laboratory diagnosis for Thalassemia”. Intensive course for thalassemia diagnosis, Division of Laboratory Diagnosis, Department of Public Health, Bangkok Metropolitan, Bangkok, Thailand, February 29, 2008.
44. “Red cell membrane diseases”. Department of Biochemistry, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, February 8, 2008.
45. “Revolution in the treatment of iron overload”. Clinical Practice in Pediatrics 2007: Health Oriented Approach. Pramongkutkoal Hospital College of Medicine. Bangkok, Thailand, December 11, 2007.
46. “Anemia in children and iron chelation treatment in Thalassemia”. Lecture tour, National Institute of Child Health, Ministry of Public Health, Bangkok, Thailand, January 29, 2008.

47. “Current approach in common causes of anemia in childhood and novel management”. Department of Pediatrics, Prapinkaow Hospital, Thai Navy, Bangkok, Thailand, January 25, 2008.

48. “Basic Science Research” Course on Research Methodology, Department of Research & Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, December 4, 2007.

49. “Practical management of iron overload”. Department of Pediatrics, Faculty of Medicine, Chiang Mai University, November 13, 2007.

50. “Practical and effective oral iron chelating therapy”. Luncheon symposium on Practical and effective oral iron chelating therapy for transfusional iron overload; the silent killer, Century Park Hotel, Bangkok, October 19, 2007.

51. “Update on Molecular Genetics of Thalassemia”. The Joint Symposia; Medical Genetics Update 2007 7 Second Genetic Metabolic Symposium. Bangkok, Thailand, November 6-7, 2007

52. “Update on pathophysiology in Thalassemia” and “update on oral iron chelation therapy in Thalassemia”. The 13<sup>th</sup> National Thalassemia Conference, Miracle Grand Hotel, Bangkok, Thailand, October 4-5, 2007

53. “Thalassemia diagnosis and pitfalls” and “Review of current iron overload treatments for clinical practice and management goals”. Exjade Educational Meeting “Turning the Science of iron overload into iron chelation practice. Kirimaya Resort & Spa, Kho Yai, Nakornrajchsrima, September 29-30, 2007.

54. “Update on thalassemia management”. Rajchaburi Regional Hospital, Thailand, August 21, 2007.

55. “Update on thalassemia management”. Maharaj Nakornarachasrma Regional Hospital, Thailand, August 14, 2007.

56. “Laboratory diagnosis for thalassemia in the symposium: Laboratory Diagnostic Technology for Thalassemia”. The 50<sup>th</sup> Anniversary Conference of Faculty of Associated Medical Technology 2007, Impact Arena, Bangkok, Thailand, June 26, 2007 (invited speaker).

57. “Update on thalassemia management; a focus on blood transfusion and iron chelation therapy”. The 6<sup>th</sup> Annual Meeting for World Thalassemia Day, Thalassemia Foundation of Thailand, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, April 29, 2007.

58. “Update on molecular genetics of thalassemia in Thailand”. The 46<sup>th</sup> Annual Siriraj Medical Conference, Thai Navy Convention Centre, Bangkok, Thailand, March 7, 2007.



59. “Molecular basic of hereditary persistent of fetal haemoglobin (HPFH)” in Symposium; Fetal globin induction-can it cure  $\beta$ -thalassemia. The 46<sup>th</sup> Annual Siriraj Medical Conference, Thai Navy Convention Centre, Bangkok, Thailand, March 7, 2007.

60. “Molecular pharmacogenomics” and “Ribosomes in bone marrow failure syndrome” in Refresher Course for Haematologist: Update on Hematology-3, Thailand Society of Hematology, Aekpilin Resort & Spa, Kanjanaburi, Thailand, February 10-11, 2007.

61. “Discovering new paradigm in human molecular genetics from a classical mendelian disease”. Seminar in Medical Biochemistry. Faculty of Medicine, Khon Khen University. Bangkok, Thailand, January 23, 2007.

62. “Discovering new paradigm in human molecular genetics from a classical mendelian disease”. Molecular Biology Club. Faculty of Medicine, Chulalongkorn University. Bangkok, Thailand, January 17, 2007.

63. “Iron overload: a preventable hazard”. A public education programme. Faculty of Medicine, Siriraj hospital, Mahidol University. Bangkok, Thailand, December 23, 2006.

64. “Clinical approach to anemia in childhood”. Tips and tricks in Paediatric Emergency, an annual paediatric conference, Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, November 15-17, 2006.

65. “Clinical application of IEF in differential diagnosis of hemoglobinopathy in Thailand”. Special seminar on an application of distinguished technique, Iso-Electric Focusing (IEF) in Hemoglobinopathy Screening and Diagnostics. Swisotel Le Concorde Hotel, Bangkok, Thailand, October 3, 2006.

66. “Common pitfalls in thalassemia diagnosis”. The 33<sup>rd</sup> National Scientific Conference: Hematology 2006: Common Pitfalls in Hematology, Thailand Society of Hematology, Hilton Phuket Arcadia Resort & Spa, Phuket, Thailand, October 13, 2006.

67. “Update in thalassemia”. Continuing Medical Education in Paediatrics. Program for pediatricians and senior nurses from the Philippines, Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Bangkok, September 9, 2006.

68. “Simple solutions of iron overload management”. Novartis Hematology Day. Evason Hua Hin Resort, Hua Hin, Thailand, September 2, 2006.

69. “New paradigm in human molecular genetics from a classical mendelian disease”. Research Club in Molecular Medicine. Faculty of Medicine Ramathibodi Hospital, Mahidol University. Bangkok, Thailand, August 21, 2006.

70. “Introduction to research question”. A training course for routine to research proposal development (R2R). Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, July 25, 2006.

71. “Common hematologic problems”. Training course on Pediatrics for Bangladesh College of Physicians and Surgeons (BCPS). Department of Paediatrics, Faculty of Medicine Siriraj Hospital, Bangkok, July 13, 2006.

72. “Clinical manifestation and management of thalassemia”. Training course for prevention and controls of severe thalassemia. Department of Health, Ministry of Public Health. Mareuw Garden Hotel, Bangkok, Thailand. July 12, 2006.

73. “Thalassemia” and “Red cell membrane disorder”. Tutorial in Pediatric Hematology. Shangrila Hotel, Bangkok, Thailand. May 21, 2006.

74. “Molecular genetics in thalassemia”. Hematology: Translating Sciences to Clinical Practices. The Annual Meeting of Thailand Society of Hematology. March 27, 2006.

75. “Cancer epigenetics” and “Present & future therapeutic potentials in thalassemia” in Refresher Course for Haematologist: Update on Hematology-2, Thailand Society of Hematology, Thawarawadee Resort & Spa, Prajeanburi, Thailand, February 4, 2006.

76. “Genotype-phenotype interaction in paediatric patients with Hb H disease”. Update on Thalassemia Conference, Royal City Hotel, Bangkok, Thailand, November 14, 2005.

77. “Current Approach in Paediatric Anemia”. The 37<sup>th</sup> National Paediatric Conference, Ambassador City Hotel, Cha-Um, Thailand, April 27-29, 2005.

78. “Gene regulation in hematopoiesis” and “Thalassemia” in Refresher Course for Haematologist: Update on Hematology-1, Thailand Society of Hematology, Rayong Resort, Rayong, Thailand, February 15-16, 2005.

79. “Genotype-phenotype interaction in patients with  $\alpha$  thalassaemia” The 10<sup>th</sup> National Thalassemia Conference, Radison Hotel, Bangkok, Thailand, July 29, 2004.

80. “Laboratory diagnosis for thalassemia”. Training course for prevention and controls of severe thalassemia. Department of Health, Ministry of Public Health, Bangkok, Thailand. July 22, 1998.

## **TRAINING COURSE**

Programme Director for Training Course in Laboratory Diagnosis for Thalassemia & Haemoglobinopathies, WHO Collaborating Centre for Prevention and Control of Thalassemia and Haemoglobinopathies, Bangkok 10700, Thailand, since 2007.

Program Director for Basic Nursing Care Program for Thalassemia Patients, Siriraj Thalassemia Research Network, Faculty of Medicine Siriraj Hospital, Mahidol University, March 1<sup>st</sup>, 2009, Pullman King Power Hotel, Rangnum, Bangkok.

**EXTRACURRICULAR ACTIVITIES**

- 2009-Present date** Secretary General for Asia-Pacific Iron Academy Board (APIA)
- 2009-Present date** Program Director for Basic Nursing Care Program for Thalassemia Patients, Siriraj Thalassemia Research Network, Faculty of Medicine Siriraj Hospital, Mahidol University,
- 2009-Present date** Expert reviewers for Malaysian's Clinical Practice Guideline for management of transfusion dependent thalassemia, Ministry of Health and Academy of Medicine of Malaysia, Malaysia
- 2009-Present date** Expert panels for The National Science and Technology Development Agency (NASDA) on stem cell research for BIOTEC, Thailand and Nanotechnology for NANOTEC, Thailand.
- 2008-Present date** TIF-Medical Collaborator  
Thalassemia International Federation, 2007 Strovolos, Cyprus
- 2007-Present date** Subcommittee on academics and continuing medical education, The Royal College of Pediatrics of Thailand.
- 2005-Present date** Local committee on academics and training,  
WHO Collaborating Centre for Prevention and Control of Thalassemia and Haemoglobinopathies, Bangkok 10700, Thailand.
- 1998-Present date** Editorial Board, "Thalassemia Foundation of Thailand Bulletin"  
The bulletin has been in existence for the past ten years. Its primary purpose is to serve the public awareness and increase understanding of thalassemia syndrome in Thais.
- 2000-2001** Treasurer of the Oxford Buddhist Society, University of Oxford

**Editorial Boards for:**

- International Journal of Blood Transfusion & Immunohematology
- Thalassemia Reports Journal
- Scientific World Journal
- Journal of Hematology and Transfusion Medicine (Thailand) since 2007
- Journal Medical Association of Thailand (Supplement Issue 2005)
- Siriraj Medical Journal

**Ad hoc reviewer for:**

- |                                   |  |
|-----------------------------------|--|
| • British Journal of Haematology  | • American Journal of Hematology                             |
| • European Journal of Haematology | • Genetics in Medicine                                       |
| • Acta Haematologica              | • Clinical Investigative Medicine                            |
| • Haematologica                   | • The Hematology Journal                                     |
| • Bioinformatics                  | • Archive of Medical Research and<br>Medical Science Monitor |
| • Clinical Chemistry              |  |
| • Clinica Chimica Acta            |  |

**AFFILIATIONS**

- Medical Council of Thailand.
- Royal Academy of Paediatrics of Thailand
- The Society of Haematology of Thailand
- The American Society of Hematology (ASH, international member)
- European Haematology Association (EHA, international member)
- American Diabetic Association (ADA, invited member)

**REFEREES**

1. Professor Douglas Higgs  
 Director of the MRC Molecular Haematology Unit  
 John Radcliffe Hospital, Headington, Oxford OX3 9DS  
 Tel: (01865) 222393 Fax: (01865) 222500
2. Emeritus Professor Sir David Weatherall, FRS  
 Emeritus Professor of Internal Medicine  
 Weatherall Institute of Molecular Medicine  
 John Radcliffe Hospital, Headington, Oxford OX3 9DS  
 Tel: (01865) 222 Fax: (01865) 222500
3. Dr. Richard Gibbons  
 University Lecturer and Honorary Consultant in Medical Genetics  
 Nuffield Department of Clinical Laboratory Science, University of  
 Oxford, John Radcliffe Hospital, Oxford, OX3 9DS  
 Tel: (01865) 222632 Fax: (01865) 222500

**THAI REFEREES**

1. Professor Prawese Wasi  
 Emeritus Professor in Hematology, Department of Internal Medicine  
 Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700  
 Thailand, Tel: (+662) 4197024 Fax: (+662) 4113010
2. Professor Voravarn S. Tanphaichitr  
 Emeritus Professor in Hematology, Department of Pediatrics, Faculty of  
 Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700  
 Thailand, Tel: (+662) 4197024 Fax: (+662) 4113010
3. Professor Chanika Tuchinda  
 Emeritus Professor in Pediatrics, Faculty of Medicine, Siriraj Hospital,  
 Mahidol University, Bangkok 10700, Thailand  
 Tel: (+662) 4197018 Fax: (+662) 4113010

**CAREER PLAN AND PERSONAL STATEMENT****Short term**

After I finish my postdoctoral fellowship training, I will return back to the Department of Pediatric, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand where I will continue my research on thalassaemia and hemoglobin disorders. Using all sort of genetic approaches I learnt from Oxford, I should be able to characterize the majority of the molecular abnormalities underlying thalassaemia and hemoglobinopathies found in Thai population. I will continue my major research interest on phenotypic diversity of  $\alpha$ - and  $\beta$ -thalassaemia to order to provide a better genetic counseling for such patients and study other possible modifying genes and potential of these in term of phenotypic prediction and provide measures for better treatments in patients. Moreover, I plan to use molecular approach to explore other hematological problems in Thailand.

### **Long term**

I would like to set up my own research unit in the Faculty of Medicine, Siriraj Hospital to work on all different aspects of red blood cell disorders i.e. red cell membrane defects, iron metabolism in particular hereditary hemochromatosis, red cell enzymopathies and other related tropical haematological problems such as haematological aspects of dengue haemorrhagic fever, malaria, acquired platelet dysfunction with eosinophilia and Southeast Asian Ovalocytosis (SAO) etc. I have my personal interest in anion exchanger protein (AE-1 or band 3), that its mutations can give rise to different phenotypes involving red cell membrane disorder and renal tubular acidosis. If possible, this unit will provide clinical and laboratory training for national and international scientists and physicians who are interested in tropical haematology and also offer opportunity for young doctors from the next generation in particular developing countries nearby Thailand who would like to embark to the exciting field of molecular medicine, the same prestigious chance once I received from Oxford.